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ABSTRACT OF THE DISSERTATION
Identifying and Accommodating Context Dependent Effects in Studies of
Genetic Variation and Human Disease
by
Danjuma Quarless
Doctor of Philosophy in Biomedical Sciences
University of California, San Diego, 2017
Professor Nicholas Schork, Chair
Professor Richard Kolodner, Co-Chair
Genetic variants, or changes in DNA sequence, are known to contribute to
both complex and Mendelian diseases. The identification of individual and collec-
tions of variants, both common and rare, associated with diseases can help elucidate
pathogenic mechanisms contributing to those diseases, since it is known that genetic
variants can impact gene function and drive pathophysiology. Unfortunately, there
is no consensus on the best strategies for identifying genetic associations and effects.
In fact, many methods simply involve testing each variant in the genome for associa-
tion with a trait directly, and ignore the fact that most molecular and physiological
systems are quite complex and involve a number of interacting parts. In this light,
xv
the effect of any one variant may be masked by, or interact with, other variants and
phenomena (such as environmental factors). This is a likely reason why many at-
tempts to identify genetic variants associated with most diseases have not been able
to explain the majority of the heritable component of those diseases. It is therefore
important to consider genetic association analysis methods that are sensitive to the
fact that genetic variants may exhibit effects that are “context dependent” in that
their effects depend on the existence of other variants or environmental factors.
Quantifying the extent to which genetic variants interact with other factors
remains a challenge in genetic studies. This is the case despite the fact that there have
been numerous historical studies exposing the existence of context dependent genetic
effects in very broad settings that should motivate greater concern for context de-
pendency in modern genetic association studies. For example, many model organism
studies, highly contrived in vitro studies, studies of tumor responsiveness to targeted
therapies, and general clinical studies of monogenic diseases have all suggested that
the phenotypic impact of certain genetic factors is dependent on other factors. We
believe that ignoring the genetic and overall context within which a genetic variant
is operating can negatively impact understanding disease pathogenesis and human
biology.
In the following, we explore two broad settings in which genetic background
and context can have an effect on the interpretation of the impact of genetic vari-
ation on a clinically meaningful phenotype. The first setting involves associating
genetic variation exhibited by the pathogen Methicillin-Resistant Staphylococcus Au-
reus (MRSA) and the clinical outcomes of patients harboring an infection induced by
that pathogen. Essentially, the current manner in which MRSA genetic variants are
identified requires the choice of a reference strain genome whose genetic background
relative to the strains of interest could influence the characterization, association and
interpretation of the impact of those variants. The second setting considers the iden-
tification of genetic factors that collectively influence Alzheimer’s Disease (AD) in
a manner that is dependent on the genetic background of the individuals studied
through intermediate phenotypes. We ultimately believe that the approaches and
findings in our work should motivate further research and a sensitivity to the numer-
ous contexts in which genetic variants may impact phenotype development.
xvi
Chapter 1
Context Dependent Effect
Considerations For Genomics
Research
1.1 General Introduction
Genetics studies seeking to identify casual factors associated with human dis-
ease are often highly problematic, since many confounding factors complicate their
implementation and interpretation. These confounding factors are rooted in the bi-
ological and genetic complexity of disease pathogenesis but are exacerbated further
in studies leveraging DNA sequencing and genotyping protocols. For example, DNA
extraction, sample processing, variant identification techniques, etc. as well as sta-
tistical analysis methods that can’t possibly control for all relevant parameters that
might affect a study’s results. As a result, substantial interaction effects involving
additional factors influencing disease and context dependent biological effects, which
in many instances often go unnoticed, have been identified in recent investigations.
These elements are important to consider in the elucidation of the contribution of
various factors to natural phenotype variation, particularly in the context of whole
genome sequencing (WGS) and genome-wide association studies (GWAS)1,2.
A prime motivation for the work outlined in this thesis is that it addresses the
shortcomings of current genome-wide association study (GWAS) methodologies to
1
2explain the heritable portion of most common diseases3–11. Genetic variations, single
nucleotide variation (SNVs) in particular, are known to have small individual effects
on disease susceptibility but often interact in subtle ways. Thus, more appropriate
methods are needed to understand the full context in which genetic factors impact
disease, above-and-beyond the individual effects of SNVs.
The context dependency of the effects of genetic factors is particularly im-
portant in precision medicine (PMed), through investigation of either complex or
Mendelian disease, since PMed requires the identification of drug targets that could
be specific SNVs and structural mutations. The assumption, however, is that those
genetically-mediated targets are not modified by other factors, which, again, may be
the critical oversight in GWAS methodologies. In many cases, the biology behind a
disease relevant to particular PMED is known to be rather complicated. Take as an
example cancer, where common practice often relies on treatments that target specific
somatically-acquired tumor-initiating mutations. However, many of these individual
mutation-targeting therapies fail due to preexisting mechanisms not accounted for or
THAT ARE acquired and create resistance that are unaccounted for at the time of
treatment initiation12–14. The occurrence of these mutations enables continued tumor
proliferation. Although this example is specific to the etiology of cancer, it points
out how mutations not accounted for, i.e., context specific mutations or mutations
in the genetic background, can be important for the successful treatment of cancer.
Thus, cancer mutations that are the targets of specific drugs often operate in a very
context-specific manner, given that the existence of other factors could mitigate their
success in combatting the tumor.
The context-dependency of targeted therapies and the existence of biological
and genetic bypass mechanisms confounding potential therapies are not unique to
cancer. For example, it has long been established that anti-microbial treatments tar-
geting specific pathogens often unknowingly assume a particular genetic architecture
and genetically-mediated capabilities of the pathogen for most infectious diseases. As
a result, many pathogens have eluded successful treatment, in a similar fashion to
certain tumors, through an ability to rapidly evolve mechanisms that withstand effec-
tive treatments. In addition, many complex neurological diseases, such as Alzheimer’s
Disease (AD), are known to be influenced by many factors whose complex interac-
3tions make it difficult to identify successful treatments that consider only one of those
factors15.
The biological complexity surrounding cancer, infectious disease and common
chronic congenital diseases like AD makes it hard enough to elucidate genetic mech-
anisms contributing to them that might lead to treatments, but the very process of
identifying those factors adds even more complexity. This observation motivated our
study of the choice of a MRSA reference genome, as a goal of that study was to
uncover technical sources of variation that complicate clinically-meaningful interpre-
tations of MRSA genome associations. For example, WGS and genotyping protocols
for identifying genetic variants that might be implicated in cancer, infectious disease
and common chronic diseases use constructs, like reference genomes, that may not be
suitable for the identification of all the relevant genetic factors.
These observations suggest that gene and DNA variations responsible for hu-
man diseases do not work in isolation, but rather have effects that are ‘shaped’ or
influenced by the activities of other genes and variants. In addition, current strate-
gies for assembling and characterizing genomes in anticipation of mining them for
important, clinically meaningful genetic variants are also impacted by the assump-
tions they make about the variation they are interrogating. In this light, there is
overwhelming evidence in the scientific literature that the ‘background,’ primarily ge-
netic background, in which a specific variant can be identified and in which it operates
biologically influences both the identification and the ultimate effect of the variant,
ultimately suggesting that the genetic background associated with a specific variant
creates a true ‘context specific’ manner in which genetic variants can be character-
ized and have an influence on a human disease. See figure 1.1 for a diagram of the
complexity associated with disease gene identification.
1.2 Terminology
The term “genetic background” has numerous definitions in the biomedical
literature. However, it historically denotes the phenomenon whereby the phenotypic
penetrance or expression of one genetic factor, such as a specific SNV or structural
variant, can influence the expression or function, or lack thereof, of a second genetic
4The Interplay of Genetic Background and Disease Risk
Figure 1.1: Figure from Bourgeron et. al (2015): A) Panel depicting various disease
burdens. B) Disease transmission may occur through multiple paths: a de novo highly
penetrant mutation (far left), a medium burden of rare variants passed on from each
parent (left of middle), if one parent has a medium load of common risk variants
and one has medium burden of rare risk variants (right of middle), and lastly when
children develop disease where both parents have a high dose of common risk variants
(far right).
factor. This type of interaction can often affect a phenotype of interest in a non-
additive manner16. In this context, the regulated factor in question that is influenced
by the presence or ability of another factor, is often said to be “modified” by the
other factor. Most human phenotypes are known to be under control of extensive
collections of genes, where variations in many of these genes contribute to the total
phenotype variation and hence modify each other’s effects. Ignoring modifiers is
known to confound research studies16–18.
The term ‘epistasis’ originally described phenomena in which the penetrance
of one gene could be suppressed by a modifying gene. However, its current use in
biomedical literature refers to other sorts of modifications impacting phenomena be-
yond gene expression. In addition, other forms of interactions are known to occur,
including gene-environment interactions that could themselves complicate character-
izations of variant interactions occurring both within the gene, i.e., SNV-SNV in-
teractions, or between variants in different genes19,20. In all, terms such as genetic
background, modifying factors, epistasis, and additional terms such as synergism,
interaction deviation, intragenic complementation and others21, all convey the fact
5that genetic variants often act in a context-dependent or context-specific manner and
they will be treated as more or less synonymous and used throughout the remainder
of this thesis.
1.3 Examples of Context-Specificity from Biological
Studies
Publications in the genetic and biomedical literature going back centuries have
noted the non-trivial difficulty in identifying context dependent effects, including the
rediscovery of Mendel’s laws of genetics22. These difficulties mainly derive from the
large sample sizes necessary to detect the often-subtle context-specific effects that
contribute to many phenotypes. Although there in notable exceptions, mostly in the
model organism literature, this fact and others have resulted relatively few specific
investigations characterizing context-dependent effects involving very specific genetic
variants or factors in the human biomedical literature. Many studies, however, have
considered the gross or overall effects of disease modifying factors, as will be discussed
later. In addition, there is growing interest in studies investigating human context
specific effects that leverage multiple high-throughput genome sequencing technolo-
gies and other ‘omics’ technologies (transcriptomics, proteomics, metabolomics, etc.).
In fact, these studies could allow researchers to potentially identify all variants and
other genomic factors that interact with a primary genetic factor of interest23,24 and
further could be motivated by and extend historical attempts to characterize instances
where genetic context impacts a biological outcome, as described below.
1.3.1 Basic Eukaryotic Model Organism Studies
Multiple historical investigations have exploited inbred mouse strains to assess
the transfer of genes and genetic variants from one strain to another25,26. These
studies demonstrated the importance of genetic context and motivated researchers
to consider their implications for human disease. For example, many mouse studies
have shown that the transfer of a gene with a lethal embryonic mutation in one
mouse strain could actually lead to viable mice when implanted in a mouse strain
6with a different genetic background23,27–29More recently, it has been estimated that
approximately 74% of all variants that modify the effect of a specific mutation, the
optomotor-blind gene, in Drosophila are dependent on the genetic background of
strains studied.4,5. The authors of the study investigating the optomotoer-blind gene
ultimately noted that the genetic background effects on the expression of the mutant
were likely underestimated in the study, and that the wider consequences of such
genetic influences are poorly understood5,6. Finally, Kruglyak and colleagues showed
that many phenotypically-impactful variants in yeast had effects that were modified
by the genetic backgrounds of different yeast strains3.
1.3.2 Cancer and Treatment Response
As noted in the introduction, it is well-documented that cancer is initiated
and sustained by the coordinated activities of multiple oncogenes, often harboring
inherited and somatically-acquired mutations, and the activities associated with spe-
cific gene and protein networks30. For example, Vogelstein et al. recently reviewed
the current state of knowledge about tumorigenesis in various cancer types and con-
cluded that each tumor is likely a product of multiple primary driver mutations in
addition to the activities and impact of many subtler ‘backseat’ driver mutations.
These secondary mutations often work independently and in tandem, such that if one
mutated gene is therapeutically targeted, other mutated genes sustain tumor growth
and may initiate metastasis by circumventing any targeted treatments focusing on
a single mutated gene. In addition, it has been shown recently that tumors acquire
copies of growth sustaining genes, such as housekeeping genes, and lose copies of
tumor suppressor genes during the evolution of the tumor. Such gains and losses
provide a unique ‘permissive’ background for tumor growth, allowing the primary
driver mutations to thrive and work in an uninhibited environment31. In addition, it
is becoming increasingly clear that tumorigenesis is not only influenced by de novo
acquired somatic mutations, but also by variants present in the host genome, as some
inherited germline variants may themselves create a more permissive environment for
tumorigenesis while increasing cancer susceptibility32.
71.3.3 Human Ancestry and Disease
It has been shown unequivocally that disease prevalence rates vary by country,
community affiliation, and geoethnic origins. For example, genetic differences between
ethnic groups are known to modify the association of specific disease-causing variants
with disease risk and transmission33. This is often attributed to dietary and cultural
differences between the population groups, but also to genetic differences between
populations34. As a result of genetic background differences between individuals that
modify specific variant effects, individuals that are admixed between different popu-
lations (e.g., African Americans, Hispanics, Brazilians, etc.) often exhibit phenotypes
and disease rates that are intermediate between the two relevant parental populations,
suggesting that genetic background does indeed influence human phenotypic expres-
sion and can modify the effects of individual variants associated with a particular
disease of phenotype in the population at large.35,36
1.3.4 The Polygenic Model of Human Diseases
Recent studies have sought to determine the degree to which the combined or
collective effects of genetic variants, each with a minor or non-substantive phenotypic
effect, contribute to a disease state37–39,39–41. Such studies suggest that most complex
human diseases do indeed have a large polygenic, or genetic background effect, which
contributes to their manifestation. Although this may make it difficult to identify
each and every variant contributing to a particular disease, given the small effect
each individual variant may have on the disease, it does suggest that the cumulative
effects of many variants shape phenotypic expression. This further suggests that the
genetic ‘context’ of an individual shapes their phenotypic presentation, i.e. the state
of gene expression, protein levels, metabolic profile, physiologic function, and overt
clinical profile in vivo 7. Also, there are many examples in the literature where a
small number of genes or genetic variants have been shown to influence a phenotype,
also suggesting that the genetic background context within which a gene or variant
operates is important to consider in the assessment of the contribution of any one
gene or variant3.
81.3.5 Infectious Disease Caused by Bacterial Pathogens
Many antibiotic agents target individual genetic regions of essential genes,
which are responsible for bacterial fitness42. Resistance to these therapies can arise
if mutations, as small as individual nucleotides in conserved genes throughout the
genome, arise that counteract the mechanism targeted by the therapy. It is now
well accepted that infectious diseases caused by bacterial pathogens can reach epi-
demic proportions due to evolutionary mechanisms involving the accumulation of
mutations that allow them to survive and overcome most antibiotics and interven-
tions43,44. This suggests that a host’s defense mechanisms cannot always deal with
a pathogen and creates the potential for host-pathogen interactions influencing the
evolutionary mechanisms that contribute to sustained human infectious disease. In
this light, it is well known that host genetic background and a particular pathogen
may be better ‘matched’ and lead to a symbiotic or mutually beneficial relationship45.
A number of studies on this particular topic have investigated the ability of host and
pathogen genetic background to contribute to disease pathogenesis as well as shape
features of bacteria46–49.
1.3.6 General Gene x Environment Interactions
There is a great deal of literature on the modifying influence of gross envi-
ronmental factors on the impact of a gene or genetic variant on disease susceptibility
or general phenotypic expression in humans50. For example, lactose intolerance is
known to be influenced by genetic variants, but only really manifests in societies with
sufficient access to milk51–53. Other well-known examples that need further study and
validation include obesity and diabetes, many forms of cancer and addiction, all of
which are likely influenced by gene-environment interactions54–56.
1.3.7 General Epistasis the Non-Additive Effects of Genetic
Variants
As noted, epistasis involves the interaction between multiple biological inter-
mediates such as proteins, genes, SNVs, and other factors, and is known to contribute
9to both disease susceptibility and organismal function. Epistatic effects can be re-
vealed through either direct biological studies or statistical analyses by identifying
non-additive effects of combinations of factors. However, methods in to identify bi-
ological or statistical epistasis have particular challenges57–60. Both In vivo and in
vitro systems and strategies exist to characterize epistasis, although identifying spe-
cific genes and/or mutations for potential analyses is not trivial for many reasons, not
the least of which has to do with cost of testing thousands or millions of potential
interacting factors61. Some statistical methods for detecting epistasis that do not
just consider individual variant associations seek to statistically prioritize collections
of SNVs for study in laboratory assays. As such, potential epistatic events identified
through statistical analyses could reveal non-additive or multiplicative effects that
may explain missing heritability of a disease or reveal novel drug targets that can
be further assessed in focused laboratory investigations62. A caveat with statistical
association-based epistatic screens is that they often suffer from difficulties associ-
ated with validation and replication in different data sets, whereas lab based epistatic
screens often do not. Despite this, an advantage of sophisticated ‘big-data’ analytic
methodologies for assessing interactions is that they can be used to screen thousands
of genetic and phenotypic variables at fractions of the cost and time compared to
functional assays and prioritize findings for further study.
Interestingly, in the context of Alzheimer’s disease (AD), evidence suggests
that APOE variants exhibit epistatic, or context dependent effects. For example,
the 4 allele is known to impact disease in a dosage dependent manner where two
copies more than doubles the disease odds ratio. However, having either an 2 or 3
allele decreases the odds of having AD even if an 4 allele is present; and possessing
two 2 alleles can protect against AD development63. These complexities suggest
that the ApoE is involved in a number of processes controlling AD pathogenesis that
may involve interactions of the sort that could be teased out via statistical meth-
ods. In addition, as mentioned, ethnicity and ancestral genetic background, which is
a measurable genetic phenomenon, can impact differential disease associations. For
example, African-American and Hispanics show weak disease association with the 4
allele, although individuals from a Caucasian and Japanese ethnic background exhibit
more pronounced allele dosage dependent effects of 4 allele64. These phenomena are
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likely attributable to epistatic or context-specific interactions amenable to statistical
analyses, but not likely to be identified through conventional additive disease mod-
eling65. One hypothesis we explore is that APOE, specifically the 4 allele, interacts
with groups or collections of other SNVs in a manner that would be missed by simple
pairwise interaction-based association testing, or an assessment of the additive main
or marginal effects or individual genetic variants.
1.4 The Genomics Era and Context-Specificity
1.4.1 Sequencing and High-Throughput Technologies
The advent of affordable genome-wide DNA sequence interrogation tools, such
as genotyping microarray chips and high-throughput sequencing technologies, has en-
abled a data-driven biological era. Through these technologies, researchers can probe
genetic aberrations throughout the genome for their association with diseases using
genome-wide association study (GWAS) strategies66. Given the massive amounts
of data that modern genetic and genomic technologies generate, particularly in the
context of GWAS strategies, the challenges that impede their use to elucidate the
biological complexity of diseases involve computational efficiency, management and
storage of data, and mathematical and statistical analysis of data. This is in distinc-
tion to a great deal of biomedical research in the past where the solutions needed for
many problems were biological or chemical in nature having to do with the creation
of appropriate laboratory assays.
In this light, contemporary genomic studies currently need analytical meth-
ods that can: 1) robustly associate the vast number of DNA sequence variations with
relevant clinical disease phenotypes via GWAS strategies; 2) Accommodate complexi-
ties, such as interactions between genetic variants, environmental factors, and general
context dependencies in association studies; and 3) correct for the incredibly large
number of statistical calculations needed to test each variant, or combination of vari-
ants and other factors, for association with disease. This chapter will address these
three issues and describe methods to improve the GWAS analysis and the interpre-
tation of information resulting from GWAS.
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1.4.2 GWAS and Statistical Analyses
Since the first draft of the human genome was published in 2003, subsequent
genomic studies have sought out to identify genomically-mediated pathophysiologic
factors that positively or negatively modulate disease expression, either under the
assumption that these factors involve multiple loci (i.e., complex ‘diseases’), or one or
a few individual loci (i.e., Mendelian ‘diseases’).67 These efforts led to the initiation of
the GWAS era of genetic studies, in which naturally occurring DNA sequence variants
throughout the genome are interrogated or ‘genotyped’ on a large number of individ-
uals either with or without a phenotype of interest or measured on a specific quantita-
tive phenotype such as weight or cholesterol level, and tested for association with the
phenotype using traditional statistical methods, such as linear regression methods for
quantitative traits or logistic regression methods for qualitative traits68,69. Identifying
genetic variants influencing diseases is particularly important because these variants
can be used to predict disease risk and aid the development of novel therapeutics by
revealing drug targets. To date, the NHGRI GWAS catalogue, which records the re-
sults of GWAS and is maintained by the National Human Genome Research Institute,
lists ≥ 29,000 SNV-disease or SNV-trait associations that pass simple criteria for sta-
tistical significance (e.g., P(x) ≤ 5.0x10ˆ-8) for hundreds of Mendelian and complex
diseases. However, as noted, the majority of these associations fail to explain large
portions of the heritable components of more complex, polygenic disease70.
Given the abundance of genomic data generated from genomic sequencing and
high-throughput genotyping technologies, GWAS analyses have become rooted in the
“Small N, Large P” statistical and mathematical problems, which have increasingly
become commonplace in many research challenges. Thus, genomic analyses typically
involving relatively small samples size (N) that have been leveraged to collect a large
number of variables (P), such as phenotypes or genetic information.71 The problem
with these types of analyses is often low statistical power to draw compelling infer-
ences, given the small sample size and the number of statistical tests which require
a multiple hypothesis test correction. In the context of the AD studies that we
have investigated and will discuss below, N=14,000+ Alzheimer’s disease patients
and controls have been evaluated for P=3,000,000+ DNA variants. It is expected
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in such studies that the majority of variants will exhibit little or no association with
disease72; however, a small subset of these variants will demonstrate an association
with disease. In this light, the problem of most pressing concern is trying to distin-
guish the appropriate true association ‘signals’ from the background ‘noise’ induced
from all the other non-associated variants. In addition, for most diseases, like AD,
the belief is that they have many genetic determinants with weak effects that are
likely to be context specific, resulting in genetic studies that ultimately explain a far
lower proportion of the heritability of the disease than originally anticipated since the
identification of variants with weak effects in genome-wide studies requires very large
sample sizes. Ultimately, then, deciphering the root genetic cause(s) of the complex
and multigenic nature of most chronic conditions, like AD, can be considered largely
a data analysis and large-scale study design endeavor.73,74
1.4.3 GWAS and Context-Specific Genetic Effects
As noted, a major problem inherent to GWAS methodologies, and genetic as-
sociation studies in general, is that the majority of variants in the human genome
that could be interrogated are simply not associated with the disease. In addition, if
an association can be detected, it is typically not very strong for a variety of reasons,
including not accounting for interactions involving the relevant gene or variant7,75,76.
Despite implicating thousands of disease variants, the traditional or canonical single-
variant-focused GWAS framework used to date will likely fail to explain the relation-
ship between genetic variants and disease since it ignores complexities, like genetic
interactions. One can argue that to overcome this issue, one could increase statistical
power to detect the effects of individual loci through the analysis of larger samples.
However, this may not work when certain types of interaction are at play.16 This is
not to devalue the utility of current association analysis efforts or the entire paradigm
of GWAS, however, but to suggest that improving the power of variant detection via
association analysis could involve statistical analysis models that consider more than
just the marginal effects of genetic variants and robustly account for and explore
interactions.
The challenges associated with identifying pairwise or interacting variants are
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apparent when considering more complex phenotypes, e.g., diseases associated with
the genomically complex antimicrobial resistance or neuropsychiatric disorders, that
are known to be among the most heterogeneous in terms of phenotypic presentation
and causal etiology. Complex pathologies and phenotypes are thought to arise from
perturbations in multifaceted gene networks, the interplay between multiple genetic-
factors which influence biochemical and biophysical processes, or environmental fac-
tors that exacerbate genetic effects.
As discussed in the previous sections, the analysis of epistatic interactions
and general context-specificity of disease-mediating factors is typically not pursued
because of the additional statistical and computational burden involved, i.e. “Small N,
Large P”. For example, without knowing which variants may be interacting, one may
test all possible combinations of variants for a potential interaction effect. With an
initial dataset of millions of genetic variant, this would create an astronomical number
of statistical tests. Thus, although it is recognized that gene-gene, gene-environment,
SNV-SNV, and other interactions exist and influence disease, and may potentially
produce genetic effects on par with the main effects of individual genetic variant,
they are hard to tease out with standard statistical analysis methodologies. Of the
methods proposed to assess gene-gene or SNV-SNV interaction effects, for example,
the majority of them exhaustively test all gene or SNVs for association in a pairwise
fashion, creating an enormous statistical problem given the need to correct for multiple
hypotheses.77–85 Alternative statistical methods could elucidate combinatorial effects
missed in traditional single locus or SNV association studies, however. For example,
in the context of our analysis of AD, we propose a two-step, nested logistic regression
approach to testing the hypothesis that a particular variant known to be associated
with a disease influences or interacts with the collective or combined effects of many
other variants. We apply this approach to the study of Alzheimer’s disease (AD).
In particular, we are interested in characterizing the ability of the 4 allele in the
Apolipoprotein E (ApoE) gene to interact with and/or modulate groups or collections
of other SNVs, possibly throughout the genome. This approach obviates the need
for directly testing all possible individual SNV-SNV interactions that could number
in the tens of millions, if not more. We apply this two-step approach to a set of
SNVS thought to be associated with AD obtained from the NHGRI GWAS catalogue.
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Ultimately we find some evidence that the e4 allele modulates the influence of a
group of other susceptibility SNVs on AD, but only in the context of the cohorts that
have been studied, with the ADGC data. We also consider analyses that explore
the identification of variants impacting infectious disease and show that the current
techniques for identifying variants in a pathogen and then relating them to a clinical
outcome in the host is very context-specific, and ultimately requires care and an
attention to detail that precedes testing specific interactions involving those variants.
We also show that despite this issue, DNA sequencing of pathogens does often result
in more confident clinical classification of pathogens than standard culture-based
methods.
1.5 Overview and Organization of Dissertation
The examples and issues discussed in the previous sections demonstrate both
the interest in, and inherent difficulties associated with, characterizing the context-
specific effects of genetic factors influencing disease susceptibility and general pheno-
typic expression. Genetic background and general context-specificity may be subtle
and impact even the bioinformatic and assay workflow used to identify and character-
ize genetic factors and their relationship to a phenotype. This suggests that a variety
of bioinformatics and statistical genetic analysis methods are needed. Ultimately,
we hypothesize that failure to control for genetic background and general context-
specificity, e.g., multiple genetic loci interacting to influence disease, may lead to: 1.
confounding effects and mischaracterization of the contribution of genetic factors to
disease; 2. variability across studies when associating disease outcomes with genetic
factors, especially in clinical contexts; and 3. a need for sensitivity to the design and
implementation of studies, limitations of data analysis methods, and clinical genetic
assay interpretation. As an example of this last point, consider researchers devel-
oping genetic assays for mutation detection in clinical diagnostic settings that focus
on the identification of single mutations where the result could mislead prognoses if
the mutation of interest has an effect that is modified by another gene or genetic
background as a whole. We have embarked on three different studies designed to
characterize the context-specificity and the effect of genetic background on human
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diseases. First, in chapter 2, we explore the utility of DNA sequencing relative to
traditional culture-based methods in the context of identifying bacterial pathogens in
the clinical setting. Second, in chapter 3, we explore the context-specificity of genetic
variant identification protocols involving the MRSA pathogen and show how they
can impact clinical interpretations about the severity and outcomes of the infection
in humans. Third, in chapter 4, we consider the influence of a single genetic factor,
the much-studied APOE4 locus on the impact of a number of other AD susceptibility
variants and show that these variants have differential effects depending on whether
an individual does or does not have the APOE4 variant and in what set of individuals
the study is pursued in. Fourth, in chapter 5, we consider the identification genetic
variants that influence AD by considering whether they influence gene expression
levels that are ultimately associated with AD via mediator-wide association study
(mWAS) methodology. We conclude in Chapter 6 with a general discussion of the
results, limitations of the studies and areas for future research.
Chapter 2
Clinical Bacterial Species
Determination by Whole-Genome
Sequencing: A Proof of Concept
Study
2.1 Abstract
Whole-genome sequencing (WGS) has drastically improved bacterial pathogen
identification, which is crucial for diagnosing and managing infectious disease. WGS
technologies present potential advantages over current complex, labor-intensive, and
often slow clinical laboratory identification practices. However, few studies have ad-
dressed the clinical validity of WGS to accurately determine bacterial species. We
compared the performance of WGS and traditional laboratory-based methods to iden-
tify species from 354 bacterial cultures collected from routine clinical microbiology
laboratory practices in the Scripps Hospital system in Southern California. To de-
termine pathogen identity, contiguous DNA sequences from cultures were assembled
and aligned against the NCBI genome database, where species identification was
defined as ≥97% assembly similarity with a database species across ≥35% of that
speciesâĂŹ genome. Laboratory identification methods were defined by Clinical Lab-
oratory Standards Institute (CLSI) protocols established at the Scripps Microbiolog-
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ical Laboratory. Our results showed the WGS approach adequately determined 35
distinct species for 339 samples (95.8 of the total), which closely matched the 340
samples with species determinations by the clinical laboratory methods. Discordance
between routine clinical and WGS protocols occurred in 29 of the 339 samples (8.6),
in addition to 17 samples where WGS detected additional bacterial species that met
the WGS match criteria. We conclude that WGS identification methods utilized in
conjunction with the NCBI database provided more resolute species determinations,
at a lower cost, and shorter turnaround time. Nonetheless, a more comprehensive
genome database and improved species match thresholds may be necessary for WGS
adoption in routine clinical pathogen identification strategies.
2.2 Introduction
Bacterial infections cause roughly 16% of annual deaths, which significantly
impacts global rates of morbidity and mortality. Management of antimicrobial in-
terventions and therapies for infectious disease critically rely on efficient pathogen
identification. However, current clinical pathogen identification practices are often
labor-intensive, costly, and slow86. Emerging whole-genome sequencing (WGS) tech-
nologies routinely characterize research grade bacterial genomes and could potentially
improve clinical microbial pathogen identification strategies. However, clinical imple-
mentation of WGS identification is not common-place, despite the first complete bac-
terial, Haemophilus influzenzae, having been sequenced in 199587. In addition, the
current National Center for Biotechnology Information (NCBI) genomic database
contains complete genomes for over 5,000 bacterial species, and numerous bioinfor-
matic tools exist to accuratley compare the genomes of clinically isolated bacteria
which could be exploited in clinical settings88.
Many large-scale epidemiological research projects have leveraged WGS in
ways that could be of clinical relevance. For example, retrospecitve WGS studies
have elucidated transmission dynamics for outbreaks associated with Escherichia
coli, Vibrio cholerae, Klebsiella pneumoniae, and Mycobacteria 89. Real-time high-
throughput WGS methods have also uncovered primary outbreak sources of hospital
infections caused by methicillin-resistant strains Staphylococcus aureus (MRSA)90,91
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vancomycin-resistant Enteroccocus facecium, and carbapenem-resistant Enterobacter
cloacae 92. Despite these examples, additional validity and feasibility studies are still
required are motivate the routine implementation of WGS technologies for clinical
pathogen identification. Thus, to investigate the performance of WGS-based bac-
terial pathogen identification, we compared a WGS-based identification strategy to
a traditional Clinical Laboratory Standards Institute (CLSI) identification protocol.
The two methods were applied to 354 clinical isolate cultures collected from a standard
routine clinical microbiology workflow not screened for specific pathogenic features
and thus reflect the incidental pathogenic variation arising in routine clinical care.
2.3 Methods
2.3.1 Sample Collection
We obtained 354 bacterial specimens from the Scripps Heath system-associated
Sorrento Mesa Microbiological Laboratory in Southern California. Potentially pathogenic
samples were collected from various body sites and cultured overnight. Resulting
colonies were then inoculated on two duplicate plates: one for clinical laboratory test-
ing and one for WGS sequencing analysis. The clinical laboratory bacterial species
identification strategy adhered to the following CLSI guidelines: direct microscopic
examination, gram-staining, elective media culture, and biochemical assays. The BD
PhoenixTM Automated Microbiology System further analyzed all colonies to confirm
bacterial species determinations and antimicrobial susceptibility.
2.3.2 DNA Processing and Whole-Genome Sequencing
DNA was extracted from 354 bacterial isolate plate colonies using ThermoFish-
erâĂŹs ChargeSwitch technology, and prepared for sequencing using the Illumina
Nextera XT library preparation kit. Libraries were rapidly sequenced on an Illumina
HiSeq 2500 sequencer. Single-ended, 50-bp reads were generated in batches of up to
48 samples. Read coverage ranged from 15 -247 apart from three low-coverage out-
liers. Sequence reads were trimmed for quality using the trimmotmatic tool and were
subjected to reference-free de novo read-based assembly (Velvet assembler V1.2.10,
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k-mer seed = 25)93. All computational analyses were performed on the Triton Shared
Computer Cluster at the San Diego Super Computer Center (8 or 16 cores per node).
2.3.3 WGS Species Determination Based on NCBI Database
Matching
BLAST+ V2.2.29 was used to align assembled contiguous sequences (contigs)
for each bacterial isolate against the NCBI genomic database, which at the time of
analysis (November 10, 2014) contained over 28,000 whole bacterial genomes93,94.
Quality matches for common species were based on the nucleotide (nt) collection
of finished assemblies. However, uncommon species samples required querying the
whole-genome shotgun (wgs) database of unfinished assemblies. Custom Perl scripts
processed BLAST outputs, identified optimal contig matches, and derived match
metrics, i.e. matched contigs frequency, DNA species match length (nucleotides), and
species length above a specified identity threshold. Adequate species determination
for individual samples was defined as ≥97% identity with a species in the database
across ≥35% of the species’ genome.
2.3.4 Partial Genomic Matches
Custom Perl scripts assessed samples exhibiting partial contig matches to mul-
tiple closely related database species and discrepant identifications between the WGS
and the clinical laboratory methodologies. The average nucleotide identity and match
length between the assembled genomes and the additional database matches were then
calculated.
2.4 Results
2.4.1 Bactria Sample Distribution by Culture Sources and
Species
178 of 354 (50%) presumed pathogen samples were from wounds; 79 samples
(21%) from blood and sterile sites; and 43 samples (12%) and 42 samples (12%) from
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sputum and urine, respectively (Table 1). This represented a typical communal dis-
tribution of common bacterial pathogens. Using the previously described thresholds,
WGS adequately determined bacterial species in 339 of 354 samples (95.8%), which
was comparable to the 340 clinical laboratory species determinations. WGS methods
revealed 15 inadequate samples (Table 2.1). Figure 2.1 (complete list in Table S5
of the Supplementary Appendix) describes the frequencies of the 35 distinct bacte-
rial species adequately identified by the WGS species determination method. The
most common pathogens were Staphylococcus aureus (35%), Escherichia coli (15%),
Enterococcus spp. (13%), Coagulase-negative Staphylococcus spp. (8%), and Pseu-
domonas aeruginosa (6%) (complete list in Table S5). Didelot, et al., reported a
similar common bacterial pathogen species distribution86.
Figure 2.1: Species Distribution for 346 samples with a single species adequately
determined by WGS. Histogram depicts the occurrence frequency of WGS based
sample identification where a subset of samples disagree with laboratory identification
methods.
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Figure 2.2: Left Panel: Depicts the distribution of matched coverage, i.e., the
matched blast length divided by length of genome of determined species. Right
Panel: Distribution of assembly coverage, i.e., assembly length divided by length of
genome of determined species.
Table 2.1: Distribution of bacterial samples by culture source. Additional informa-
tion includes the result species determination by WGS and the clinical laboratory.
2.4.2 Clinical Laboratory Species Determination
337 of 354 bacterial samples initially had complete clinical laboratory species
determinations. 17 samples exhibited incomplete results, 13 determinations with only
genus specifications and 4 characterized either “mixed flora” or “skin contamination”,
which are common when microscopic or biochemical examinations suggest a non-
pathogenic species. WGS provided adequate species determinations for 13 of the 17
unidentifiable samples. Beyond incomplete species determinations, 21 other samples
returned discordant species determinations between the laboratory and WGS meth-
ods. This raised human intervention error concerns for the laboratory method, i.e.
multiple handlings or poor sensitivity. To assess the reproducibility of the laboratory
determinations and also which method, laboratory or WGS, might be problematic, the
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laboratory determination process was repeated on the 23 discrepant samples. Species
determination results were updated in 12 of these 23 samples (Table S7). After repeat
testing, 6 originally discordant samples became concordant between the two methods
tested, while the remaining 6 samples remained discordant (2 with incomplete species
information).
The clinical laboratory initially determined 37 bacterial species in 337 samples;
the remaining 17 samples had incomplete species information, with 13 determined
only to the genus and four characterized as “mixed flora” or “skin contamination”.
The latter characterizations are common when routine microscopic examination and
biochemical assays suggest the species are not pathogenic. WGS adequately deter-
mined the species in 16 of the preceding 17 samples. In addition to the samples with
incomplete species determination, 24 others had an initial laboratory species that did
not fully agree with the WGS species. This suggested possible handling errors and
poor sensitivity for the laboratory species determination. To assess its reproducibility,
23 samples (20 with discordant determinations) were returned to the laboratory for
repeat testing, and the species information changed in 12 of these samples (Table S7
of the Supplementary Appendix). Whereas none of these 12 samples had agreement
between the WGS and laboratory species initially, six agreed after repeat sequencing.
The number of samples with incomplete species determination decreased from 17 to
14.
2.4.3 Whole Genome Sequencing Species Determination
Contigs from 339 samples with adequate WGS species determination matched
almost exclusively to a single species (Table 2.4). However, 29 samples had sizable
matches (longer than 300kb) to multiple species (Table 2.6). For 25 of 29 samples,
investigations revealed the total lengths of additional matched assemblies were com-
parable to, or less than, the lengths of the original matched genome. This implied that
25 samples contained a single species; however the remaining 4 samples inadvertently
contained two species, as denoted by the additional database matches. The resulting
adjustment to single and multi-species matched coverage samples is reflected in the
“Adjusted” column of Table 2.1.
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To support our adjustments, we noted that all 29 discordant samples exhib-
ited nearly identical DNA content based on additional BLAST optimal strain matches
(Table S4). Indeed, matched species results for 22 of these samples had Latin names,
while other NCBI matches returned only numbered ID identifiers. Numbered IDs in-
dicate these NCBI genomes may not characterize fully complete species as that desig-
nation typically corresponds to named species. Also, 2 of the 24 samples matched to
two clearly distinct NCBI database species, which potentially indicates contaminated
entries. To determine the species of each adjusted sample, either the longest named
species match or the correct species in the case of a database error was chosen. One
single-species sample matched to two species with numbered IDs that were not close
enough for adjustment which suggests inadequate species determinations.
For the 354 samples that underwent WGS analysis, Figure depicts the matched
coverage sample distribution, i.e., matched contig length ≥97% identity for the best
species divided by a typical genome length for that species. For the 24 samples with
adjustments, we added the matched lengths of the species that were nearly identical
at the DNA sequence level to calculate the matched coverage. The matched coverage
threshold was set at 35%, due to 339 samples (95.8%) falling above 40%. Figure
shows the corresponding assembly coverage sample distribution, i.e., the assembly
length divided by the best matched species typical genome length, which is greater
than 55% in all cases. The triangles in the figure correspond to the four samples with
multiple WGS species results, which had assembly coverage values between 129% and
249%.
15 samples failed the NCBI database match criteria and were deemed inad-
equate for WGS species determination. 13 of these samples had long assemblies;
however, they exhibited drastically low read coverage which is calculated by total
read length multiplied by total sequencing reads, divided by genome length (Table
2.9). When the identity threshold was relaxed from 97 to 95%, seven of the nine
sample coverage values were increased substantially. We hypothesize our WGS pro-
cedure likely produced correct species identifications for these samples, apart from
three with only numbered IDs. Four samples had leq2% matched coverage at geq97%
identity, thus have no proximal NCBI database genome matches.
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2.4.4 Wgs and Clinical Laboratory Discrepant Species Deter-
minations
Of the 339 samples with adequate WGS species determination, only 29 were
discrepant with the laboratory determination, even after repeat clinical testing. Upon
separating discordant samples into four categories (Table 2.2)), Category 1 contained
11 samples where the clinical laboratory species determination failed. Eight of these
samples were determined only to the genus, and three samples were deemed iden-
tified incomplete by laboratory testing. This highlights two potential limitations of
current laboratory procedures: 1) subjectivity by laboratory technicians; and 2) poor
biochemical assays sensitivity, although this limitation may be specific to less com-
monly annotated bacterial species and not inherent to the laboratory method. In
Category 2, 12 samples had complete species determination by the clinical labora-
tory and agreement with WGS to genus, but not species. For 10 of these samples,
the NCBI database contained whole genomes of the laboratory species designations,
however WGS species method matched more robustly than the laboratory-determined
species. This suggests the laboratory determinations were less accurate. The two re-
maining samples in Category 2 were not in the NCBI database and thus whether a
concordant species determination exists remains unclear.
In Category 3, 2 samples had discrepant genus species determination. Cate-
gory 4 had four samples that contained two WGS species, but only one laboratory
species result (WGS not fully determining both species in one of these samples).
Nonetheless, these events suggest WGS methods may potentially improve multiple
pathogen identification events compared to the more stringent laboratory practices.
Category 3 contains two samples that did not agree even to the genus. Cate-
gory 4 contains four samples that had two species according to WGS, but only one
according to the laboratory, which indicates that WGS is better able to identify mul-
tiple pathogens in a single sample. Even though our WGS procedure was unable to
determine the species of four samples, the laboratory species for three of those were
inconsistent with the WGS data (Table S6 of the Supplementary Appendix). Since
the laboratory species are in the NCBI database, they would have been found by our
procedure if they were correct.
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Table 2.2: Clinical isolates with adequate WGS species determination status which
partially of fully failed to agree with the clinical laboratory determinations (N=34).
The culture source distribution of the 29 discordant samples was similar to the
distribution of the collection at large. However, a heterogeneous species distribution
was observed among discordant samples (Figure 2.1). No disagreement was seen
in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa; however
coagulase-negative Staphylococcus spp. and other clinically uncommon species caused
a high-percentage disagreement events. These results indicate that WGS can produce
higher resolution and accurate bacterial species determinations for at least the more
common species.
2.4.5 WGS Cost Efficiency in Real-Time Clinical Applications
Cost and turnaround time is crucial for real-time clinical implementation. The
costs associated with our WGS method were approximately $50 per bacterial genome,
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which includes the costs of bacterial cell culture, DNA extraction, library preparation,
and sequencing(Table 2.3). Sequencing technologies are rapidly advancing which has
significantly decreased associated costs over the past decade (estimated WGS cost
in 2012 was $150 per isolate) [7]. Didelot, et al., estimated a cost of $25 per Mb of
assembled sequence, and bacterial genomes typically range from 2-6 Mb86.
Table 2.3: The cost, turnaround time, and major limitations of WGS and clinical
laboratory determinations of bacterial species.
To replicate the typical community hospital microbiology lab workload, 48
samples were processed per WGS analysis batch. Genomic sequences were obtained
approximately 18 hours after bacterial colonies were available for a 48-sample pool (3
hours for DNA extraction, 3 hours for library preparation, and 12 hours for sequenc-
ing). A similar WGS turnaround time was reported by Hasman et al.95, which roughly
compares to routine clinical laboratory turnaround time. Bioinformatic species de-
termination analyses required <1 hour per sample and all samples can be computa-
tionally processed in parallel.
2.5 Discussion
Currently, clinical laboratories follow a variety CLSI guided methods for pathogen
identification which rely on organism culture and phenotypic characterization, i.e.
gram staining and biochemical properties. These processes are complex, time-consuming,
and often species-specific with variable sensitivity and specificity. WGS, in conjunc-
tion with comprehensive reference genome databases and highly-accurate bioinfor-
matic workflows, can ultimately resolve and infectious microorganism identities, at
potentially greater resolutions. Our study demonstrates that WGS-based bacterial
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species identification is at least as accurate as laboratory methods, which highlights
the growing validity of WGS as a scalable clinical microbiology diagnostic tool with
low-cost and short turnaround time.
Over a third of the 29 discordant species determinations between the two
methods had incomplete laboratory results; i.e. they returned as mixed flora or co-
agulase negative Staphylococcus (CoNS). Incomplete laboratory determinations were
more probable when pathogenicity was âĂĲruled outâĂİ during the initial CLSI ex-
amination. However, informing clinicians of these types of pathogen identification
discrepancies is crucial, particularly because previously recognized non-pathogenic
strains have emerged as pathogenic. CoNS bacteria commonly colonize skin and
mucosa and had long been considered non-pathogenic infections. However, as in-
travascular device use increases, CoNS infections have become a major cause of noso-
comial bacteremia96. A blood culture sample in our study was initially determined
as Staphylococcus epidermidis by WGS and MRSA by clinical laboratory testing re-
spectively. Upon repeat laboratory testing, the sample identity was determined as
CoNS, thus becoming concordant with the WGS determination. Interestingly, the
mecA gene that confers β-lactam resistance, i.e. methicillin, was found in the DNA
sequences of this sample. MRSA and CoNS are are closely related, thus a mischar-
acterization event based on the phenotypic contribution of methicillin resistance is
possible. Mischaracterizations events such as this example can introduce variability
in disease management by causing heterogeneous clinical treatment and outcomes.
Certain bacterial species demonstrated more frequent clinical laboratory mis-
characterization, including Enterococcus faecalis and faecium, CoNS, and Klebsiella
spp. Exemplifying Enterococci, the most reliable laboratory testing schemes for differ-
entiating Enterococcus faecalis and faecium from other Enterococcus species includes 8
procedures: acid production from sorbose, sucrose, ribose and l-arabinose, utilization
of pyruvate, deamination of arginine, motility, and pigment production on tellurite97.
Efficient rapid and cost-effective strategies to identify the Enterococcus genus relies on
antibiogram analysis, which requires continuous surveillance and is region-specific98.
The complexity of existing laboratory testing schemes, with poor sensitivity and
specificity, complicate optimal pathogen characterization approaches. Moreover, the
application of our WGS methodology led to the identification of additional pathogens
28
in one blood culture sample, where the antibiotics necessary for the two distinct infec-
tions often varies amongst physicians, e.g., WGS identified Enterococcus faecalis and
Staphylococcus aureus while the clinical laboratory only identified Enterococcus fae-
calis. Antibiotics necessary to combat these two distinct infections often vary amongst
physicians. Thus, misdetection of additional pathogens through standard laboratory
methods could confound patient care and significantly increase the occurrence of ad-
verse events, especially in patients presenting bacteremia. Antibiotics necessary to
combat these two distinct infections often vary amongst physicians. Thus, misdetec-
tion of additional pathogens through standard laboratory methods could confound
patient care and significantly increase the occurrence of adverse events, especially in
patients presenting bacteremia.
An unintended, yet important, finding was poor reproducibility of the clin-
ical laboratory. Twenty-three discordant samples were sent for repeat testing and
species results differed for more than half. Six initially discordant samples agreed
completely with WGS after repeat. This error rate was unexpectedly high and thus
raised concerns regarding human handling errors in current gold-standard identifica-
tion methods. Exemplifying one blood culture sample, WGS returned Enterococcus
faecalis while clinical laboratory initially returned Streptococcus parasanguinis and
then Enterococcus faecalis after repeat. Clearly, initial mischaracterizations could
mislead clinicians and produce differential diagnostic decisions.
2.5.1 Method Limitations
Elements of our proof-of-concept study suggest two major limitations of WGS
determination methods to routinely identify bactieral species: (1) genome databases
lack comprehensive bacterial representation, which will likely improve as additional
bacterial genomes are deposited into the NCBI database; and (2) appropriate com-
putational sequence matching thresholds are uncertain. Our threshold of geq97%
identity and geq35% coverage is based upon similar studies99, which conducted a
study that leveraged 28 bacterial genomes in six phylogenetically distinct groups
and determined the 95% threshold sufficient to delineate species. A more extensive
study100 involving 536 pairwise genome comparisons from the NCBI database sug-
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gested an average nucleotide identity (ANI) threshold of 95-96%, which is closer to
our study and the more stringent ANI threshold (Table 2.9). We leveraged a highly
stringent threshold to ensure confident species determinations and the highest degree
of clinically applicability. Nonetheless, bacterial species identification can be ambigu-
ous because genomic variation in each species is non-uniform. As additional WGS
studies are completed, the uncovered distribution of genomic variation in bacterial
species, within and between bacterial species, will reveal more reliable DNA based
differentiators as opposed to continued use of phenotypic differentiators.
Two extensions could futher improve clinical WGS approaches. First, drug re-
sistance profiling during species determination would improve pathogen surveiliance
efforts. ARG-ANNOT is a recently developed drug-resistance gene database with po-
tential101, however comprehensively investigating its clinical effectiveness is necessary.
Second, cultureless species determination of patient samples from WGS could greatly
reduce human errors compared to laboratory methods, and has been demonstrated
previously95. However, the necessary metagenomic analyses are more computation-
ally demanding, and will likely complicate processing samples from various sources.
2.6 Conclusion
WGS combined with the NCBI database is able to determine the species of
most bacteria typically found in a clinical setting with high resolution, low cost, and
short turnaround. Nonetheless, a more comprehensive reference genome database and
validated species identity thresholds may be necessary for clinical implementation of
WGS.
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2.9 Supplemental Appendix
2.9.1 Species Delineation By Average Nucleotide Identity
To compute the average nucleotide identity (ANI) between a sample genome
and a genome in the NCBI database, we used a variant of the algorithm adopted
by Goris, et al.102. Instead of splitting the sample genome into 1-kb fragments for
the alignments with BLAST103, we just used the variable-length contigs. Often each
database genome also consisted of multiple contigs, rather than a single chromosome,
so this worked as well when comparing two database genomes. In all cases we used
the default blastn settings. By contrast, Goris, et al., used alternate settings to obtain
better sensitivity when comparing two distantly related genomes, but we were most
interested in closely related genomes. By comparing ANI and DNA-DNA hybridiza-
tion values for 28 bacterial genomes in six phylogenetically distinct groups, Goris,
et al., concluded that two genomes with an ANI value above 95% that covers more
than 69% of the genomes are within the same species. They also showed that the
ANI value and its coverage are highly correlated, so it is often sufficient to just report
the former. In a much more extensive study involving 536 pairwise comparisons of
genomes in 85 groups from the NCBI database, a species delineation threshold of
95-96% ANI was observed104. They further noted that two genomes with an ANI
value between 94% and 96% are in a “transition zone" within which it is less certain
whether they are the same species or not.
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2.9.2 Illustrative Output for WGS Species and Strain Deter-
mination
To illustrate the information obtained from our WGS analysis, we provide
results here for a typical sample: 2014-043. Its Velvet assembly generated 538 contigs
with a total length of 2,704,594 b. The longest contig had a length of 96,326 b, and
the N50 value was 34,602 b. The assembly took 2 min 27 s running on 8 cores of
an Intel Sandy Bridge processor. The subsequent BLAST analysis with blastn, using
-max_target_seqs 1 and default settings otherwise, found the best match for each
contig against all of the genomes in the NCBI database as of November 10, 2014.
For Sample 2014-043 this took 28 min 11s on 16 cores of two Intel Sandy Bridge
processors.
Two Perl scripts that we wrote processed the BLAST output. These binned
the best matches of the contigs by species and by strain above our 95% identity
threshold and then output the corresponding number of matching contigs and the
total length of the matches. These scripts took less than a second to run. Outputs
for Sample 2014-043 are shown in Tables 2.4 and 2.4. Table 2.4 shows that practically
all contigs of the assembly match to Staphylococcus aureus genomes in the database.
The few matches to genomes of other species are presumably due to contamination
or incorporation of short segments of DNA from the other species in the genome of
our sample. Table 2.4 shows that the matches are too many different strains of S.
aureus. The strain with the longest match length is S. aureus A8117.
Evolution of the NCBI Database
At the outset of our study we downloaded the NCBI database as of January
23, 2014 to SDSC, and this was used for the initial BLAST alignments of all of our
samples. We found several genomes that had been assigned incorrect species and
reported them to NCBI. By the time that our study was nearing completion, many
more genomes had been added to the database, so we downloaded a newer version as
of November 10, 2014. We used this to reanalyze all samples with inadequate species
determinations by WGS or ones for which the WGS and laboratory determinations
disagreed. We found several samples with much better matches using the newer
database, and these improved results are those reported here. We also found that
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two errors we reported had been corrected, though another one affecting our results
had been added.
As the NCBI database continues to grow, the BLAST run times will likely
increase. If this is deemed a problem, the local version of the database could be
restricted to a smaller subset of relevant genomes.
2.9.3 Long Match/Multiple Species WGS Samples
Most samples had long matches to a single named species as shown in Table
2.4. However, some samples had long matches to multiple species, and these required
further investigation. Table 2.6 contains information on the 33 samples that initially
appeared to contain multiple species, since they had relatively long matched lengths
of >300 kb to two to four species. However, examination of the assembly coverage
for these samples suggested that all but four contained only a single species. To
characterize these samples, we separated them into four categories in the table.
Category 1 of Table 2.6 contains 25 samples with long matches to multiple
species, at least one of which has a numbered ID. According to NCBI, such unnamed
isolates “are clearly distinct from currently recognized species [and] are tentatively des-
ignated at the species level". These unnamed isolates have not yet been characterized
by traditional methods, or the species name has not yet been validly published." Such
species are unknown to a clinical laboratory and cannot agree with the laboratory-
determined species, which are named. This led us to ask how close genomically the
multiple matching species are to each other and, especially, whether the species with
numbered IDs are really distinct from named species. To quantify our answers, we
computed the ANI between various combinations of sample-strain and strain-strain
pairs. Some relevant results are shown in Table 2.7, and four are discussed here.
Sample 2014-038 has long matches to Enterobacter cloacae UCICRE 5, Enter-
obacter hormaechei YT3 Enterobacter MGH 1, and Enterobacter MGH 33. As shown
in Table 2.7, all four strains have ANIs ≥98.7% relative to the sample. Thus they
seem to be the same species, which we took to be E. cloacae because of its longest
match. It also agrees with the species determined by the laboratory, but calls into
question the validity of the E. hormaechei YT3 strain being within a named species
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distinct from E. cloacae in the NCBI database. Sample 2014-272 has long matches
to Aeromonas hydrophila 173, Aeromonas MDS58, and Aeromonas dhakensis AAK1.
All three strains have ANIs ≥96.9% relative to the sample and between each other.
Thus they seem to be the same species, which we took to be A. hydrophila based upon
its much longer match to the sample. This also calls into question the validity of A.
dhakensis AAK1 being a strain within a named species distinct from A. hydrophila in
the NCBI database. The laboratory-determined species was Aeromonas sobria, which
is not in the NCBI database. Sample 2014-330 has long matches to Corynebacterium
ATCC 6931 and Corynebacterium HFH0028. Relative to the sample, the first strain
has an ANI of 96.4, while the second strain has an ANI of 95.4. These two strains
are close genomically, with an ANI between them of 94.9, which is just below the
95 species identity threshold of Goris, et al 2.7. Neither strain has a Latin species
name, however, whereas Corynebacterium amycolatum SK46 does and has an ANI
relative to the sample that is only slightly lower at 94.5. We took the latter, named
species to be that of the sample and adjusted the matched length to be the sum of
the lengths for C. ATCC 6931 and C. HFH0028. Note that the laboratory also had
difficulty identifying the species of this sample and reported it as “Mod Corynebac-
terium species, not JK”. Sample 2014-352 has long matches to Sphingomonas S17
and Sphingomonas paucimobilis NBRC 13935, and the two strains have ANIs ≥99.3
relative to the sample. Thus they are clearly the same species, which we took to be
S. paucimobilis, even though its match was shorter. By comparison, the laboratory-
determined species was Elizabethkingia meningoseptica. The ANI value between the
sample and E. meningoseptica 502, a typical species, is 79.0 (and only over a very
short portion of the genome), so the laboratory determination is incorrect.
2.9.4 Multiple Close Species in Different Genera Samples Matches
Category 2 of Table 2.6 contains two samples that had long matches to both
Stenotrophomonas maltophilia RR-10 and Pseudomonas geniculata N1. These strains
assigned to different genera have an ANI between them of 96.2, so they are actually
the same species, namely Stenotrophomonas maltophilia, which has been noted before
[S7].
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2.9.5 Two Distant Species Long Matches Due to NCBI Database
Error
The two samples in Category 3 of Table 2.6 had long matches to NCBI genomes
of very different species because of errors in the database. Sample 2014-356 had long
matches to Morganella morganii F675 and Strongyloides ratti. The latter is a ne-
matode, not a bacterium, so it was likely contaminated with M. morganii when the
genome was sequenced. Similarly, Sample 2014-370 had long matches to Staphylo-
coccus capitis QN1 and Balansia obtecta B249. The latter is a fungus, which again
was presumably contaminated with S. capitis during sequencing. Samples with high
assembly coverage that really did contain two species Category 4 of Table 2.6 con-
tains four samples that had high assembly coverage and so really did contain whole
genomes from two different species as well as from different genera.
2.9.6 Adequate Coverage Matches To Numbered ID Species
Five samples had longest matches of adequate coverage to a species with a
numbered ID. Two of those, 2014-330 and 2014-352, each had two long matches as
discussed previously and were determined to be Corynebacterium amycolatum and
Sphingomonas paucimobilis, respectively. For a third sample, 2014-170, our WGS
procedure gave only a single long match to Corynebacterium HFH0082 with an ANI
of 98.1% as shown in Table S4. However, this sample also matches Corynebacterium
amycolatum SK46 with an ANI of 95.2%. Thus we took the latter species with a
Latin name to be the one determined by WGS. By contrast, the laboratory initially
determined the species to be Enterobacter cloacae and changed that to Klebsiella
pneumoniae after repeat testing. The ANI value between the sample and K. pneu-
moniae MGH 18, a typical species, is 79.9% (and only over a very short portion
of the genome), so the laboratory determination is clearly incorrect. For two other
samples, 2014-276 and 2014-286, our WGS procedure gave only a single long match
to Staphylococcus HGB0015 with an ANI of 95.2%. Since the NCBI database had
no species with Latin names that gave close matches, we took the preceding species
with a numbered ID to be that determined by WGS. These two samples were the
only ones with adequate matched coverage for which we could not find a genomically
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equivalent species with a Latin name. The clinical laboratory determined the species
for these samples to be Staphylococcus schleiferi, which is not in the NCBI database.
Thus it is possible that the WGS and laboratory species are, in fact, the same.
2.9.7 Distribution by species of samples with a single species
adequately determinated by WGS
Table 2.8 shows the distribution by species of the 346 samples for which our
WGS procedure adequately determined a single species after the preceding adjust-
ments were made. There are 39 distinct species.
2.9.8 Samples with inadequate species determination by WGS
and their associated ANI values
Using our threshold of ≥95% identity across ≥25% of the genome, WGS was
unable to determine the species for only four samples. These are in the lower left
corner of Figure 2A and are the first four listed in Category 1 of Table 2.10, where
the samples are ordered by matched coverage. The remaining 13 samples in Category
2 of the table have the next lowest matched coverage values of ≥25% but <70%, so
these all have adequate species determinations. Also listed in the table are the ANI
values between each sample and the WGS species as well as between each sample and
the laboratory species when it was determined and in the NCBI database. All of the
samples in Category 1 have ANI values well below the 95% species identity threshold
of Goris, et al. 2.7, and all of the samples in Category 2 have ANI values above
the 95% threshold, except for the two Stenotrophomonas maltophilia samples with a
slightly lower ANI of 93.1%. Three other samples in Category 2 have ANI coverage
values below 69% because of low read coverage and so might not strictly pass the
species identity requirement of Goris, et al. On balance, though, our species identity
threshold and that of Goris, et al., seem nearly equivalent. The first three samples of
Category 1 have laboratory species with very low ANI values. This indicates that the
laboratory species determination was not correct for these. Table S7 contains results
for those samples with repeat species determination by the clinical laboratory.
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Table 2.4: Output of BLAST matches binned by species for Sample 2014-043
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Table 2.5: Complete output of BLAST matches binned by strain for Sample 2014-
043.
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Table 2.6: Samples that appeared to contain multiple species upon initial analysis
by WGS (n=31).
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Table 2.7: Distribution of samples by species adequately determined by WGS.
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Table 2.8: Distribution of samples by species adequately determined by WGS.
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Table 2.9: Samples with <70% matched coverage at ≥95% identity (n=19).
Table 2.10: Distribution of samples by species adequately determined by WGS.
Chapter 3
Implications of Methicillin-Resistant
Staphylococcus Aureus (MRSA)
Reference Genome Choice for
Investigating Clinical Correlates
3.1 Abstract
Methicillin-Resistant Staphylococcus Aureus (MRSA) is an opportunistic in-
fectious pathogen of epidemic proportions. Recently, technological advancements
have enabled reference guided whole-genome sequencing (WGS) of bacterial genomes.
This has uncovered vast heterogeneity in the function of single nucleotide variations
(SNVs), which complicates the process of associating clinical phenotypes, genetic pro-
file elements, and antibiotic resistance because SNV based investigations depend crit-
ically on the contents of the reference genome. Multiple reference genomes have been
utilized throughout the scientific literature. However the contribution of individual
reference genomes is unknown for MRSA analyses. We hypothesize that additional
sources of variation in DNA sequencing protocols can significantly confound investi-
gations aiming to elucidate pathogen-related genetic virulence associations. Analyses
aimed to interrogate this genetic variation, either within or across pathogen strains,
must assert assumptions concerning the most optimal reference genome or comparator
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strain.
To assess the effect of incorporating multiple reference genomes on investiga-
tions aiming associate clinical phenotypes with pathogen virulence factors, we imple-
mented identical WGS analytic pipelines with two different MRSA reference genomes
used in literature. DNA Sequences, antibiogram drug resistance, and patient response
data were collected for 302 bacterial cultures isolated from routine clinical microbi-
ology laboratory workflows. We describe strategies for multiple reference genome
implementations while observing that bacterial reference genome strain can adversely
influence clinically relevant claims about pathogenicity which can confound clinical
studies. We find that clinical correlations differ amongst reference strain utilization
and argue that care must be taken in pursuing studies of genetic variation in complex,
highly variable pathogens such as MRSA.
3.2 Introduction
Combatting infectious disease is a critical medical concern among industri-
alized and developed countries, where hospital and community acquired bacteria
account for a significant proportion of global morbidity and mortality. Staphylo-
coccus aureus is considered one of the most virulent multi-drug resistant pathogens,
which may attribute its virulence and evolutionary capabilities to functional factors
present throughout the genome105–109. It is well known that genetic elements aug-
ment pathogen virulence capabilities to rapidly evolve, adapt, and overcome the most
sanitary hospital environments110. Great genetic diversity reflects this increase in in-
fection rate and proliferative ability, which is largely due to 1) a substantial lack in
efficacious drugs to treat pathogenic infections; 2) the much-recognized ability of in-
fectious pathogens to adapt and develop genetic and biological mechanisms to evade
therapeutic interventions, and 3) the wide-spread overuse and improper medical ap-
plications of antibiotic treatment109,111–115. Efficient and powerful high-throughput
screening platforms, i.e. genomic sequencing and antibiotic profiling technologies,
has shed light on the degree to which genetic elements influence andor correlate with
clinically-relevant outcomes86,112,116–118. Specific genetic factors associate with indi-
vidual phenotypes, however additional work is needed to uncover their complex inter-
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play with pathogenicity, environmental pressures, and host-related factors45,119–121.
Computational, and statistical hurdles impede associating genetic factors for
drug resistance with clinical outcomes122, not the least of which concern the inherent
biological complexity. Thus, bacterial infection is complicated, where DNA sequenc-
ing based investigations critically depend on DNA sequence protocols and their ability
to differentiate signal from noise90,123–125. Typically, millions of genome sequencing
‘reads’ (i.e., relatively small stretches of DNA sequence) captured by sequencers need
to be reconciled, ordered and ‘assembled’ in order to identify differences (i.e., vari-
ants) in the genomes and their associations with clinical outcomes126. This process
can be pursued completely unbiased through ‘de novo assembly’ methods, that exclu-
sively utilize reads and no reference genome to reverse engineer particular bacterial
genome127–129. Unfortunately, de novo assembly approaches are computationally and
strategically intensive, especially for comparatory investigations130,131. Therefore,
reference-guided approaches, which match sequencing read(s) to a previously char-
acterized genome, are implemented to aid target pathogen genome reconstruction,
which inherently uncovers differences between the target and the reference genomes.
These differences may reveal clinically meaningful DNA associations. However This
raises the challenge of identifying the most optimal or proximal reference genome
which may impact conclusions made about the target genomes in question.
3.2.1 Bacterial Virulence Determination Deficiencies
Clinical and Laboratory Standards Institute (CLSI) antibiogram protocols de-
fine gold-standard assays for the clinical practice of determining drug resistance132. In
attempts to surpass binary drug response indications, high-throughput DNA sequenc-
ing instruments have aided antiobiogram protocols by characterizing highly variable
individual mutations that contribute to the genetic architecture of drug resistance. A
recent study investigating the genotype-phenotype relationship of MRSA antibiotic
resistance demonstrated a 99.8 percent correlation between 12 antibiotics based on
193 MRSA samples124,133,134, which implicated genetic penetrance as a mechanism for
antibiotic resistance and pathogenicity. Thus, laboratory or sequencing methods that
limit the number of DNA factors, i.e. specific gene regions, mutations, etc, may fail
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to account for the full context of DNA functionality inherent in genome. This may
potentially confounding research investigations aimed at identifying the biological
underpinnings of infectious disease.
3.2.2 Antibiotic Resistance
Decreasing the prevalence of antibiotic resistance by understanding its genetic
contributions would benefit the medical community. Over the past two decades,
rates of β-lactam targeting methicillin, vancomycin, and multi-drug resistant bacterial
phenotypes have unyieldingly increased. For example, resistance to the antibiotic
penicillin was observed in clinical isolate strains less than 10 years after its clinical
introduction in 1944, and the first MRSA strain was reported only one year after the
drug’s initial launch in 1975. 15 major antibiotic classes have been utilized clinically
to treat pathogenic infections, however none have eluded the emergence of untreatable
bacteria112 (Table 3.1).
Table 3.1: From left to right, columns correspond to the antibiotic class with an
example class, the year the drug was discovered, the year the compound was first
introduced in clinical practice, the year antibiotic resistance was first observed, the
Resistance mechanism of action, and the species the compound is effective for.
Antibiotic Class;
Example
Dis-
cov-
ery
Clinic In-
troduction
Resistance
Observed
Mechanism of
Action
Activity or Target
Sulfadrugs; prontosil 1932 1936 1942 Inhibition of
dihydropteroate
synthetase
Gram-positive bacteria
β-lactams; penicillin 1928 1938 1945 Inhibition of cell wall
biosynthesis
Broad-spectrum activity
Aminoglycosides;
streptomycin
1943 1946 1946 Binding of 30S
ribosomal subunit
Broad-spectrum activity
Chloramphenicols;
chloramphenicol
1946 1948 1950 Binding of 50S
ribosomal subunit
Broad-spectrum activity
Macrolides;
erythromycin
1948 1951 1955 Binding of 50S
ribosomal subunit
Broad-spectrum activity
Tetracyclines;
chlortetracycline
1944 1952 1950 Binding of 30S
ribosomal subunit
Broad-spectrum activity
Rifamycins; rifampicin 1957 1958 1962 Binding of RNA
polymerase β-subunit
Gram-positive bacteria
Glycopeptides;
vancomycin
1953 1958 1960 Inhibition of cell wall
biosynthesis
Gram-positive bacteria
Quinolones; ciprofloxacin 1961 1968 1968 Inhibition of DNA
synthesis
Broad-spectrum activity
Streptogramins;
streptogramin B
1963 1998 1964 Binding of 50S
ribosomal subunit
Gram-positive bacteria
Oxazolidinones; linezolid 1955 2000 2001 Binding of 50S
ribosomal subunit
Gram-positive bacteria
Lipopetides; daptomycin 1986 2003 1987 Depolarization of cell
membrane
Gram-positive bacteria
Fidaxomicin (targeting
Clostridium difficile)
1948 2011 1977 Inhibition of RNA
polymerase
Gram-positive bacteria
Fidaxomicin (targeting
Clostridium difficile)
1948 2011 1977 Inhibition of RNA
polymerase
Gram-positive bacteria
Diarylquinolines;
bedaquiline
1997 2012 2006 Inhibition of
F1FO-ATPase
Narrow-spectrum activity
(Mycobacterium tuberculosis)
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3.3 Overview
Bacterial resistance investigations often leverage statistical associations of ge-
nomic variation. These analyses often utilize different reference genomes as a result of
heterogeneity in DNA sequencing computational strategies (Table 3.2). We asked the
question, does a particular reference genome effect the study of a particular bacterial
population? Our investigation explored the impact of utilizing two of most widely
used and publicly available MRSA reference genomes, Staphylococcus aureus subsp.
aureus TW20 (Genbank accession number: FN433596.1) and Staphylococcus aureus
subsp. aureus HO 5096 0412 (Genbank accession number: HE681097.1) in variant
calling practices when assessing genomic DNA sequence variation of clinical MRSA
bacterial isolates. These reference genomes were analyzed in conjunction with whole
genome sequence data obtained for 302 MRSA clinical isolates from patients in a
single hospital system, and 49 MRSA DNA sequences acquired from the National
Center for Biotechnology Information (NCBI)135,136.
Our analyses suggest that the choice of a reference to guide the identification
of genetic variations does make a difference, though not necessarily a pronounced one.
We argue that the differences in clinically-meaningful associations based on reference
choice are an inevitable product of the very pathogen genomic diversity of interest
and that newer strategies for ensuring robust claims about associations between the
genomic properties of pathogens must be developed and leveraged. Problematic in-
fectious disease control of has caused alarm among clinicians, epidemiologists and
public health workers where the multidrug-resistant pathogen has significantly in-
creased global morbidity and mortality rates. Tremendous variation at the genomic
level which influences S. aureus resistance to every known antibiotic (Table 3.1, data
adapted from Lewis (2013)). Thus, understanding the genetic contribution of vari-
ability in resistance and pathogenicity phenotypes could increase treatment efficacy,
improve clinical outcomes, and highlight functional virulence mechanisms.
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Table 3.2: Summary of studies that used difference references, with columns provid-
ing the citation, the number of strains studied, the source of the strains, and what
reference was used.
Citation PMID SequencedGenomes RefG˙enome Outcomes
Laabei,
M(˙2014)125
24717264 Methicillin-resistant Sa˙ureus TW20
A predictive model based on a set of
significant single nucleotide polymorphisms
(SNPs) and insertion and deletions events
(indels) showed a high degree of accuracy
in predicting an isolate’s toxicity solely from
the genetic signature at these sites.
Md Tauqeer Alam
(2014)137 PMC4040999
Vancomycin-
intermediate
Staphylococcus
aureus (VISA)
Sa˙ureus
N315
whole-genome comparison predicted VISA
based on the presence of a rare mutationa
in a set of candidate genes.
Holmes,
A(˙2013)138
23927001
Methicillin-
resistant Staphy-
lococcus aureus
(MRSA)
HO50960412
Single nucleotide polymorphism assay for
epidemiological analysis of EMRSA-15 clini-
cal isolates.
Hsu, L(˙2015)106 25903077
Methicillin-
resistant Staphy-
lococcus aureus
(MRSA)
HO50960412
TW20
Competition between clones also has an im-
portant role in driving the evolution of noso-
comial pathogen populations.
Claudio,
K(˙2012)134
22693998
Methicillin-
resistant Staphy-
lococcus aureus
(MRSA)
HO50960412
Revealed a distinct cluster of outbreak iso-
lates and clear separation between these and
the nonoutbreak isolates.
Weng,
Z(˙2014)139
24969089
Drug-resistant
hospital-
associated
methicillin-
resistant Staphy-
lococcusaureus
(HA-MRSA)
TW20 T0131
JKD6008
The results suggest that ST239 strains iso-
lated in Hong Kong since the 1990s belong to
the Asian clade, present mainly in southern
Asia, whereas those that emerged in north-
ern China were of a distinct origin, reflecting
the complexity of dissemination and the dy-
namic evolution of this ST239 lineage.
Table 3.3: Summary (averages across the strains) of variant calls metrics across two
separate MRSA reference genomes (Table 3.2). Information compiled from mapped
bams using the flagstat command.
Reference Genome Number
of SNVs
Percent
Cover-
age
Average
Depth
Per
Base
Average
Base
Quality
Percent
Mapped
Reads
Average
Mapped
Reads
H050960412 Reference 26080 93.48 175.78 36.60 84.62 5966295
TW20 Reference 16422 88.53 179.75 36.58 87.55 5980804
3.4 Methods
3.4.1 Sample Collection and Clinical Laboratory Processing
302 bacterial cultures collected from a routine workflow in a clinical micro-
biology laboratory. Specimens were collected from various body sites and cultured
overnight. Then, resulting colonies were then inoculated on plates and then taken to
a sequencing laboratory for WGS analyses. The clinical laboratory determined the
bacterial species following Clinical Laboratory Standards Institute (CLSI) standards
with the following guidelines: direct microscopic examination, gram staining, culture
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on elective media, and additional biochemical assays. All culture colonies were fur-
ther analyzed on a BD PhoenixTM Automated Microbiology System to confirm the
bacterial species determination and test for antimicrobial susceptibility.
3.4.2 DNA Sequencing
DNA was extracted from the colonies, and WGS was performed on an Illumina
HiSeq 2500 sequencer in the rapid run mode. Single-end, 50-bp reads were generated
in batches of up to 48 samples per flow cell, with read coverage ranging from 15-247x.
3.4.3 Sequence Data Processing and Variant Calling
All computer analyses were implemented on the Triton Shared Computer Clus-
ter (TSCC) at the San Diego Super Computer Cluster (SDSC) in parallel on 8 or 16
cores within a node to minimize the run times. Our protocol utilized the ‘Reddog’
short-read length sequencing analysis pipeline (Version V1beta.10.3 070916, Calico
Cat) to perform quality based read filtering, specific reference genome FASTA se-
quence read mapping, and variant calling. The RedDog program is a software pack-
age that executes a distributed computational workflow on a specified sample set
and was chosen specifically for its streamlined analyses and pipeline reproducibility
(https://github.com/katholt/RedDog)140. The package includes necessary functions
for DNA variant calling including BWA read mapping, Genome Analysis Tool Kit
(GATSK) variant detection, and downstream analyses (SNPs only)141,142.
Additionally, complete genome sequences for 49 MRSA samples were down-
loaded from the NCBI. These samples were included to act as genetic control samples
in our analyses to account for any systemic laboratory or computational biases in our
sequencing pipeline.
3.4.4 Statistical Analyses
Variants called against the two reference genomes were utilized to formulate
a genetic distance or dissimilarity matrices, which are defined in terms of nucleotide
variant content shared across variant positions throughout the genome between each
49
pair of clinical isolate genomes. Matrices were then subjected to statistical tests to
calculate the conditional effects of each particular reference genome, where both tests
rely on the nucleotide variant distance matrix to measures the percent dissimilarity
of each species when compared to each other species in the dataset (often referred to
as a ‘Genetic Relationship Matrix’39. The first is Mantel’s statistical test for matrix
equality, which determines the degree of correlation between two square matrices (n
rows X n columns), and second being the Generalized Analysis of Molecular Variation
(GAMOVA)143,144 to measure the variance component of each clinical variable.
A genetic distance matrix compares the genetic dissimilarity of reads for each
species mapped against the H050960412 reference genome, and then those same reads
from each species mapped against the TW20 reference genome. If the MRSA refer-
ences produced no result altering genetic effects, then each individual isolate would
follow similar patterns in their placement relative to MRSA species included in the
matrix. Thus, the mapped reference would have no effect on genetic composition.
For the implementation of Mantel’s test, 1000 Permutations were used to assess the
probability that the dissimilarity of the two matrices occurred purely by chance.
GAMOVA, implemented in the ADONIS function of the R language (Vegan Package
2.3-3), leveraged the dissimilarity matrix to calculate the proportion of variance ex-
plained by clinical variables, the framework allowed use to test the hypothesis that
dissimilarity in variant profiles across the genomes of the MRSA isolates as a whole
correlated with similarity in clinical outcomes. This analysis is thus complementary
to the single locus or gene-specific analyses, since it explores the impact of the phylo-
genetic relationships between the isolates produced with the use of a specific reference
and the clinical outcomes.
3.5 Results
3.5.1 Strain Similarities as a Function of the Reference Used
After mapping reads for each isolate to either MRSA reference genome and
SNP variants were called, we assessed the number of variant sites called per clinical
isolate in addition to comparing variant calling metrics to determine mapping quality
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of each reference respectively. Variant calling metrics included base depth, percentage
of the reference genome covered, number of mapped reads, etc. A summary of these
analyses is provided in Table 3.3, where it can be seen that although many of the
mapping statistics are similar, a greater number of variants were called with confi-
dence using H050960412 reference. This increase is mostly likely a function of the
genetic distance of this particular reference genome in relation to the cohort of clinical
isolates, i.e. phylogenetic relationship which was reflected in the outcome of Man-
tel’s test. Phylogenetic divergence often comes with (or assumes) differences at the
genomic level, such that mapping reads on to the reference would inevitably expose
differences in the nucleotide content of the target and reference sequences; i.e., the
more phylogenetic divergence between the target and reference, the more nucleotide
differences. Annotating the two references for gene content lead to 736 genes being
identified with the H050960412 reference genome and 885 genes being identified on
the TW20 reference genome. The two references had 722 genes in common (80.3%).
Probably due to the greater number of variants found in the H050960412 reference
genome, there were more variants found in these 722 genes in the H050960412 refer-
ence genome (Figure 3.1; Supplementary Figure 3.4.
Figure 3.2 provides dendrograms that reflect the genetic similarity and cluster-
ing of the MRSA clinical isolate genomes based on whether the H050960412 reference
was used to identify genomic variants from each isolate in contrast to whether the
TW20 reference was used. The figure demonstrates that the clustering is not identi-
cal when the different references are used. Another graphical device, a heatmap, was
utilized to display the GRMs and they also exhibit a difference in isolate representa-
tion (Figure 3.3). Principal components analyses also suggested that clinical isolate
genomes clustered with greater more densely when the TW20 reference genome was
used as opposed to the H050960412 reference genome (Supplementary Figure 3.5). A
Mantel’s matrix equality test of the GRMs utilized in the dendogram analysis was
correlated at .508 with a permutation p-value of .001 (correlation = 0.5077231, at p(x)
= .001). This result suggests that the use of the two references generates different
relationships between the MRSA clinical isolate genomes.
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Figure 3.1: Gene Region SNV Frequency Correlation By MRSA Reference Genome
3.5.2 Clinical Associations with Clinical Isolate Genomes
We next utilized the GAMOVA statistical test to determine if the use of dif-
ferent reference genomes affected the relationships between isolate genome similarity,
clinical outcomes, and individual isolate drug resistance profiles. Table 3.4 and 3.5
presents the results of the analyses involving the clinical outcomes and Table 3.6
and 3.7 presents the results of the analyses involving the drug resistance phenotypes.
These tables suggest that the association strength and their statistical significance
differs somewhat depending on what reference is used, but the overall trends are the
same: whether the strain resulted in a pathogenic outcome, the age at which the
infection was diagnosed, the antibiotics chosen to treat the infection and the diag-
nosis at admission are all associated with isolate genome similarities. However, the
diagnosis at admission was only significantly associated if the less polymorphic TW20
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Figure 3.2: Genetic Variant Based Sample Phylogeny By Mapped Reference. SNP
variants were utilized to create a genetic distance based dendogram tree. This tree
provides the clustering of each clinical isolate sample for each of the two reference
genomes mapped against.
Figure 3.3: Genetic Variant Heatmap Visualization For Species Distance. Clustering
of clinical strains when using two different references.
genome was used as a reference.
An analyses involving the drug resistance profiles of each isolate suggest greater
concordance between the results, as the resistance profiles associated with antibiotics
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penicillin, clindamycin, erythromycin and oxacillin were found to be associated with
isolate genome similarity, but to different degrees depending on the reference used.
This was the case despite the fact the isolates exhibited great variation in the drug
resistance profiles (Supplementary Figure 3.6).
Table 3.4: ANOVA statistics for for variance explained for clinical covariates in
clinical isolates acquired from Scripps Green hospital mapped against the H050960412
reference genome.
Df SumsOfSqs MeanSqs F.Model R2 Pr(>F) Significance
Pathogenic 1 104434 104434 4.6335 0.04019 0.003996 **
Age of Infection 1 179205 179205 7.9509 0.06897 0.000999 ***
Antibiotic Duration 1 16172 16172 0.7175 0.00622 0.621379
Hospital Time (Days) 1 20353 20353 0.903 0.00783 0.508492
Vancomycin MIC 1 33526 33526 1.4875 0.0129 0.148851
Antibiotic Chosen 33 990018 30001 1.3311 0.38101 0.021978 *
Admission Diagnosis 29 758810 26166 1.1609 0.29203 0.151848
Residuals 22 495856 22539 0.19083
Total 89 2598374 1
Table 3.5: ANOVA statistics for for variance explained for clinical covariates in
clinical isolates acquired from Scripps Green hospital mapped against the TW20
reference genome.
Df SumsOfSqs MeanSqs F.Model R2 Pr(>F) Significance
Pathogenic 1 99089 99089 5.0068 0.03986 0.0037 **
Age of Infection 1 182876 182876 9.2404 0.07356 0.0002 ***
Antibiotic Duration 1 16084 16084 0.8127 0.00647 0.464554
Hospital Time (Days) 1 18768 18768 0.9483 0.00755 0.460954
Vancomycin MIC 1 25607 25607 1.2939 0.0103 0.222778
Antibiotic Chosen 33 936206 28370 1.4335 0.37658 0.007999 **
Admission Diagnosis 29 772023 26621 1.3451 0.31054 0.043296 *
Residuals 22 435398 19791 0.17514
Total 89 2486050 1
Table 3.6: The ANOVA outcome statistics for variance explained when the antibi-
ogram drug response data was compared to the SNP dissimilarity matrix derived from
variant calls against the H050960412 reference genome.
Df SumsOfSqs MeanSqs F.Model R2 Pr(>F)
Penicillin 2 101126 50563 2.2743 0.01561 0.012987 *
Clindamycin 2 1329223 664612 29.8936 0.2052 0.000999 ***
Erythromycin 2 125353 62677 2.8191 0.01935 0.008991 **
Oxacillin 2 120651 60326 2.7134 0.01863 0.004995 **
Tetracycline 2 26501 13250 0.596 0.00409 0.942058
Trimethoprim 2 29388 14694 0.6609 0.00454 0.777223
Rifampin 2 40461 20230 0.9099 0.00625 0.495504
Levofloxacin 2 58410 29205 1.3136 0.00902 0.171828
Residuals 209 4646613 22233 0.71732
3.6 Discussion
Pathogenic infections are increasingly becoming a public health issue, given the
ability of pathogens to evolve quickly and develop antibiotic treatment resistances.
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Table 3.7: The ANOVA outcome statistics for variance explained for variance ex-
plained when the antibiogram drug response data was compared to the SNP dissim-
ilarity matrix derived from variant calls against the TW20 reference genome.
Df SumsOfSqs MeanSqs F.Model R2 Pr(>F)
Penicillin 2 95759 47879 2.384 0.01505 0.030969 *
Clindamycin 2 1649395 824697 41.061 0.25917 0.000999 ***
Erythromycin 2 124387 62193 3.097 0.01954 0.008991 **
Oxacillin 2 113804 56902 2.833 0.01788 0.011988 *
Tetracycline 2 28451 14226 0.708 0.00447 0.727273
Trimethoprim 2 30881 15441 0.769 0.00485 0.583417
Rifampin 2 47602 23801 1.185 0.00748 0.320679
Levofloxacin 2 76198 38099 1.897 0.01197 0.100899
Residuals 209 4197668 20085 0.65958
Total 225 6364145 1
Identifying specific pathogen strains, genes and genetic variants that contribute to
communicable nature of a pathogen, its virulence and treatment resistances are there-
fore of tremendous importance. Unfortunately, genetically-mediated resistance mech-
anisms exploited by pathogens are complex and hard to decipher. This challenge is
further complicated by the computational and statistical manners in which genetic
variations are identified, catalogued and tested. The traditional method of identify-
ing variants in pathogen genomes, which involves mapping DNA sequence obtained
from target pathogen genomes onto a chosen reference genome, can produce unde-
sired sources of variation if the reference genome mapped against differs in terms of
gene content, structural variations, overall organization and specific nucleotide con-
tent. Our study demonstrates the consequences of reference genome choice in relating
genomic variation to clinical outcomes and drug resistance profiles.
We find obvious and expected differences in two reference genomes we chose
for study, but also differences in the outcomes of association studies involving the clin-
ical isolates when variants are identified with each of two references. Although not
pronounced, our study suggests SNVs identified from a particular reference genome
can impact an ability to identify associations between clinical isolate genomes and
clinical outcomes, however this effect was not drastic. Differential reference use to
formulate genetic distance matrices as a measure of similarity can effect the phylo-
genetic clustering of a population of bacterial isolates, which can be important in
investigations attempting to compare variant mutations from vastly different bacte-
rial species. We also find that variant call frequencies in annotated gene regions have
a strong correlation, which indicates a general uniformity between reference genomes
for MRSA.
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3.6.1 Study Limitations
We recognize that our study has obvious limits. A more comprehensive study
would have explored the use of many different potential reference genomes. We were
constrained by what was available in the public domain. In addition, we did not
explore the utility of, e.g., multiple sequence alignments, and other analyses to identify
points of divergence between the references that could have been overcome by perhaps
combining their use. We also did not consider structural variant analyses or copy
number variant analyses. Finally, our analyses were also constrained by the relatively
small number of patients for which we had clinical outcome and phenotype data and
the fact that we did not explicitly consider host-genome and other host-related factors
that might interact with pathogen-related factors to affect clinical outcomes145.
3.6.2 Conclusions
Despite these limitations, our results do suggest that care should be taken
when interpreting pathogen genome background and clinical outcome associations.
There may be, however, ways to mitigate the problems associated with a choice of a
reference genome. First, one could simply look at the sensitivity of the results when
using different references, more or less as we did. Second, one could try to combine
genome information from different references into a unique read mapping framework,
much in the way strategies like those implemented in the program GenomeMapper146.
Third, one could do away with reference mapping altogether and rely on assembly
each genome of interest de novo, although the problem of reconciling the various
positions in the target genomes subjected to de novo assembly might be problematic
despite the high quality of multiple sequence alignment tools93,147.
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3.8 Supplementary Figures
Figure 3.4: Venn Diagram of Gene Regions Shared By Each MRSA Reference
Genome. Annotations were downloaded the NCBI gene tracks.
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Figure 3.5: Principal component analysis of samples by MRSA reference genomes
Figure 3.6: Clinical Isolate Antibiogram Drug Response Data
Chapter 4
Comprehensive Gene
Expression-Based Mediator-Wide
Association Study of Alzheimer’s
Disease
4.1 Abstract
Alzheimer’s Disease (AD) is a complex, multifactorial condition that plagues
approximately 5.5 million Americans who collectively require hundreds of billions of
dollars’ worth of health care. Identifying the factors contributing to AD is not trivial
given its complexities. Mediator-wide Association Studies (mWAS), which search for
molecular and subclinical phenotypes that mediate the relationship between a ge-
netic variant and a disease, have the potential to shed light on factors contributing
to AD that can leverage genetic data from existing studies. We pursued a large-
scale mWAS for AD that exploited: 1. three very large cohorts (International Ge-
nomics of Alzheimer’s Project (IGAP), the Alzheimer’s Disease Genetics Consortium
1 (ADGC1) and ADGC2 cohorts) that collectively totaled 11576 to cases and 10796
controls (ADGC1: 9549 cases and 7683 control, ADGC2: 2027 cases and 3133 con-
trol); 2. Comprehensive gene expression and genetic data within the Genotype-Tissue
Expression (GTEx) database obtained on 44 different human tissues in hundreds of
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individuals; and 3. Proven analytical methods for conducting mWAS that also con-
sidered potential heterogeneity in the relationships between the genetic variants, gene
expression levels and AD across and within the cohorts. We ultimately found evi-
dence for a few weak associations, but little consistency in mWAS results between the
cohorts beyond tests involving the APOE gene, despite minimal statistical evidence
for heterogeneity in effects sizes among the individual subcohorts that make up the
total ADGC1 and ADGC2 cohorts. We did see compelling and replicated evidence
suggesting that expression levels in the APOE gene are associated with AD and likely
mediate the relationship between APOE genetic variants and AD susceptibility.
4.2 Introduction
Alzheimer’s Disease (AD) is a chronic neuropsychiatric disorder caused by
amyloid-plaque and neurofibrillary tangle build-up in the cortical and hippocampal
regions in the brain148–150. AD is the most common cause of dementia in many
countries, as roughly 5.5 million individuals are affected in the United States alone and
44 million are affected worldwide, and the costs associated with caring for people with
AD amounts to hundreds of billions of dollars and continues to rise151,152. Currently,
no reliable and proven therapeutic interventions exist to alter the disease progression
of AD. Thus, two critical challenges for the biomedical community are to identify
factors that contribute to AD susceptibility and progression, and to identify ways of
mitigating the effects of those factors to prevent and treat AD effectively153.
Unfortunately, AD is a complex, multifactorial disease with many genetic and
non-genetic influences whose individual contributions and interactions have been dif-
ficult to sort out150,152,154–156. Genome wide association studies (GWAS) have been
pursued to identify genetic variants that might impact AD and, outside of the well-
known Apolipoprotein  (APOE) gene, few variants of strong effect have been iden-
tified and replicated70,156–159. This is unfortunate, since the identification of genetic
variants contributing to AD could lead to insights into the molecular processes that
contribute to AD pathogenesis and reveal points for pharmacotherapeutic interven-
tion. However, recent extensions of GWAS that consider the role that an intermediate
phenotype (IP) might play in a causal pathophysiologic chain leading from a genetic
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variant to AD clinical manifestations have promise160. Mediator-wide association
studies (MWAS) leverage GWAS data along with sources of information that provide
knowledge of relationships between genetic variants and IPs to systematically test
IPs for potential causal associations with a disease of interest, such as AD, that could
be considered drug targets15,16. Unfortunately, the choice of IPs to study and their
measurement on thousands of individuals can be difficult. As a result, aspects of
the implementation of MWAS initiatives can be impractical and challenging161,162.
Unfortunately, the choice of IPs to study and their measurement on thousands of
individuals can be difficult. As a result, aspects of the implementation of MWAS
initiatives can be impractical and challenging.
Clever statistical analysis methods have been developed to overcome the need
to directly measure an IP on individuals for an MWAS. Consider the fact that it
is possible to leverage knowledge of associations between genetic variants and IPs
to build predictive models of those IPs that can then be used to impute or assign
predicted IP values to individuals with genetic variants typed on them as part of a
GWAS. In this way, the predicted IP values can then be tested for association with a
disease of interest with the GWAS data. it has been further shown that an MWAS can
be conducted using only summary statistic information resulting from a GWAS163–165.
If done properly under many testable assumptions, the principles behind Mendelian
Randomization (MR) tests can be invoked and thereby lead to statistical hypothesis
tests in an MWAS setting that can be used to investigate causal links between the
genetic variants, an IP, and a disease of interest164,166,167.
We pursued an MWAS of AD using state-of-the-field epidemiological data from
multiple cohorts, gene expression-based IP databases and state-of-the-field statistical
methods for relating the IPs, SNPs and AD diagnosis. We obtained GWAS summary
statistic data from the International Genomics of Alzheimer’s Project (IGAP) as well
as raw GWAS genotype and phenotype data from the Alzheimer’s Disease Genetics
Consortium 1 (ADGC1) and ADGC2 cohorts156,158. Together the ADGC cohorts
totaled 11,272 to cases and 10,419 controls (ADGC1: 9549 cases and 7683 control,
ADGC2: 1723 cases and 2736 control). We also used information in the GTEx
database about relationships between SNPs and the expression levels of genes in 44
human tissues from 449 donors168. Finally, we leveraged state-of-the-field statistical
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analysis methods, many associated with MR Base, a resource for Mendelian Random-
ization and MWAS tools, to carry out relevant analyses integrating the AD GWAS
and gene expression data164. These statistical analysis methods included methods for
assessing evidence for heterogeneity in the strength of the MWAS results within and
across the AD cohorts.
Our results provide evidence that suggests that APOE gene expression me-
diates the relationship between APOE genetic variants and AD. We found evidence
that other genes may have expression levels that influence AD susceptibility that
are affected by genetic variants, but the evidence for these other genes was not as
compelling as for the APOE gene. We did not find evidence for heterogeneity in
the effects of SNPs and gene expression levels on AD within or across the cohorts.
We ultimately believe that analyses like ours can shed light on potentially modifi-
able factors contributing to AD, but must be approached with a sensitivity to their
limitations.
4.3 Methods
4.3.1 ADGC Data Processing
ADGC Data Processing. We obtained and analyzed genotype and phenotype
data from the ADGC, which has been previously described21. The ADGC is made
up of 26 individual cohorts divided into an initial set of cohorts and data (ADGC1; 13
cohorts) and a replication or follow-up set of cohorts and data (ADGC2; 13 cohorts).
For each individual cohort within the broader collection of cohorts in ADGC1 and
ADGC2, we generated imputed genotype input files from the available genotype data
for GWAS and MWAS analyses. Essentially, we leveraged the Plink bioinformatic
suite (Version 1.90b3v) to convert ADGC IMPUTE2/SNPTEST Oxford-format files
containing genotype imputation probabilities available for hard genotype calls in bi-
nary Plink format. We used Plink for data processing and applied the default uncer-
tainty threshold for imputing variants to remove any imputation calls with certainty
less than 0.1. We also applied the following additional Plink filtration parameters to
remove genotypes that were problematic from the imputation protocol: variants above
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the maximum missing genotype rate of 0.02, variants violating the Hardy-Weinberg
equilibrium threshold of 0.000001, variants with minor allele frequency values below
the threshold of 1 percent, and highly correlated genotype calls arising from strong
linkage disequilibrium. Individual samples missing more than 10% of genotype calls
were also removed. We also removed individuals with missing AD phenotype status,
sex status, or APOE 4 allele designation.
4.3.2 Summary Data from the International Genomics of
Alzheimer’s Project (IGAP)
We obtained publicly available summary statistics data from the published
meta-analysis of the AD GWAS published by IGAP investigators156. Details about
the study participants’ ascertainment, data quality control, and association analyses
are described in the study9. We ultimately used the stage 1 IGAP summary statistics
dataset, which consists of 7,055,881 single nucleotide polymorphisms (SNPs) from
17,008 Alzheimer’s disease cases and 37,154 controlsÂăof European ancestry. For
each SNP, we leveraged the following information in our analyses from the available
IGAP resources: Chromosome of the SNP (Build 37, Assembly Hg19), Position of the
SNP (Build 37, Assembly Hg19), SNP rsID or chromosome position if the rsID was
not available, reference allele (i.e., coded allele), Non reference allele (i.e., non-coded
allele), overall estimated effect size for the effect allele (i.e., the Beta weight provided),
overall standard error for effect size estimate (denoted as the SE in the dataset), and
the meta-analysis GWAS p-value for the stage 1 IGAP analyses.
4.3.3 GTEx Genotype Expression Data
As noted, we considered gene expression levels as potential IPs for AD in our
analyses. We obtained information about SNP-gene expression level relationships
from the Genotype-Tissue Expression Project (GTEx) publicly available resource168.
The GTEx resource provides expression quantitative trait loci (eQTLs) based on cor-
relation analysis between genotype and tissue-specific RNA expression on 44 different
tissues obtained on 449 individuals with genotype information. We focused on pri-
marily cis-acting eQTLS. Details about the expression QTLs (eQTLs) analysis can be
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found in multiple publications by the GTEx Consortium168. For each SNP identified
as an eQTL in the GTEx database, we obtained the following information: SNP rsID,
Chromosome of the SNP (Build 37, Assembly Hg19), Position of the SNP (Build 37,
Assembly Hg19), Reference allele (coded allele), Non reference allele (non-coded al-
lele), the gene whose expression levels were associated with a SNP in given tissue (IP),
the overall estimated effect size for the associated allele (Beta), the overall standard
error for effect size estimate (SE), and the p-value reflected the statistical significance
of the association. Based on this, we extracted 187,263 independent cis-eQTL SNPs
for 27,094 genes across the 44 tissues.
The intersection between the independent cis-eQTL SNPs from the GTEx
consortium and the IGAP AD GWAS was found by matching rsID. A total of 77,854
SNPs were found in common, and used as instruments in the MR analysis. The
exposure and outcome datasets were harmonized to ensure each SNP corresponded
to the same effect allele. We tested the causal effect of cis-eQTLs for 22,878 genes
across 44 tissues on AD using the analysis tools described below.
4.3.4 Mendelian Randomization Analysis
For each eQTL from GTEx for which the associated tissue specific expres-
sion data were available to build a predictive model of the expression level, and for
which the associated SNP was also genotyped or imputed in the IGAP and ADGC
cohorts, we pursued Mendelian Randomization (MR) tests. MR tests, as noted, test
the hypothesis that the IP of interest âĂŞ in this case the expression level of a gene
âĂŞ is causally associated with the phenotype (AD) based on its association with a
SNP and that SNP’s relationship to AD. MR tests have their roots in instrumental
variables analyses169. Ultimately, in the context of instrumental variables analyses,
the genetic variants (SNPs) associated with an IP are used as instrumental variables,
the IP is considered the “exposure” variable, and the disease is the outcome vari-
able. To conduct MR tests we used, in part, two analytical techniques and associated
software available from the MR-Base resource: the two sample MR test and asso-
ciated R package âĂĲTwoSampleMRâĂİ and the âĂĲMRInstrumentsâĂİ analysis
suite developed by Hemani et al. The MR estimate of the causal effect between the
65
expression levels and AD was calculated as the Wald ratio as discussed by Hemani et
al. We considered the Fixed effects meta-analysis method (delta method for standard
errors) also available from MR-Base. To control for multiple comparisons we used a
Bonferroni correction based on the number individual mediation tests we performed.
We note that this is conservative given that many of the tests are correlated due to
linkage disequilibrium and relationships between expression values of genes within
and across tissues.
4.3.5 ADGC Cohort-Based Meta-Analyses
To assess the robustness of GWAS association metrics from each individual
ADGC1 and ADGC2 subcohort we analyzed using the Metasoft meta-analysis pack-
age (version v2.0.0)169. Briefly, plink case/control association statistics for each in-
dividual ADGC dataset, ADGC1 and ADGC2 respectively, were converted to the
standard Metasoft input format. The resulting files were then analyzed in the Meta-
soft using default run parameters, with filtering out of GWAS SNVs that reported
either a standard error of 0 or a plink unadjusted p-value of “INF”. To determine the
robustness of mWAS results, the metap (Version 0.8) was utilized in the R language
to perform meta-weight analyses of the cohort based results for ADGC1 and ADGC2.
To assess the meta-significance of MWAS results, beta scores and standard error val-
ues from MRbase outputs for each individual cohort were loaded into metasoft. This
analysis only consisted of fixed effect MR tests, which included 130,659 MWAS tests
across 90,383 unique RSID identifiers. Metasoft excludes entries where only 2 or less
cohorts have entries, which left 130,641 resulting entries.
4.3.6 Heterogeneity Analysis
To explore evidence that the strength of the association in the GWAS and
MWAS analyses varied across ADGC cohorts, we used Cochran’s Q test as imple-
mented in the software package, derived from the Metasoft package169.
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4.4 Results
4.4.1 GWAS Analyses
Figure 4.1
Figure 4.1: Manhattan plots for IGAP, ADGC1, and ADGC2 GWAS results.
ADGC1 and ADGC2 results were calculated by the metasoft meta analysis software,
where each dataset contains the corresponding individual cohorts.
Figure 4.1 provides the Manhattan plots associated with the GWAS results
for the three cohorts we analyzed. Note that IGAP GWAS results simply reflect
the summary statistics obtained from IGAP. The ADGC1 and ADGC2 plots reflect
meta-analysis p-values based on re-analysis of GWAS for each component cohort
within the ADGC1 and ADGC2 cohorts. Tables 4.1, 4.2, and 4.3 provide a list
of the top hits of the GWAS across the ADGC and IGAP cohorts, with support
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Figure 4.2
Figure 4.2: ADGC1 and ADGC2 Heterogeneity P-value QQ-Plots. Plots contain
the plotted p-value statistic for the Cochran statistic (Q) calculated by metasoft.
Although the ADGC2 QQ-plot appears to demonstrate inflation, bonferroni adjust-
ment of the p-values returns zero SNVs which remain significant. The same is true
for ADGC1. This indicates that there was no observable heterogeneity effect in ei-
ther cohort from the ADGC data, which could have downstream effects on Mrbase
analyses.
for the associations for each of the cohorts separately. Additionally, we tested each
SNP for heterogeneity of association strength with AD among the different cohorts
across the individual ADGC1 and ADGC2 subgroups for GWAS results. Figure 4.2
provides q:q plots displaying the observed p-values against expected p-values (i.e., if
no heterogeneity exists among the ADGC cohorts). It can be seen that little evidence
for heterogeneity exists in SNP association strength, as no GWAS entry surpassed
the Bonferroni significance threshold, which gives us confidence the MWAS analyses
are not likely to suffer from heterogeneity as well.
Gene Expression-Based mWAS Analyses. We conducted MWAS analyses for
the IGAP cohort and each individual ADGC cohorts for all SNPs associated with
gene expression values in the different tissues available from the GTEx database,
but limited to only genes whose expression levels could be imputed or assigned to
individuals in the three GWAS cohorts based on the availability of relevant SNP
information. This resulted in 118,292 tests for IGAP, 353,756 tests across 53,665
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Table 4.1: Top GWAS meta-analysis results derived from the metasoft program for
ADGC1.
unique entries for ADGC1, and 838,716 tests across 87,182 unique entries for ADGC2.
Meta-analysis was used to combine the MWAS results from the individual ADGC1
and ADGC2 cohorts as with the GWAS data. Supplementary Figure 1 provides q:q
plots for the GWAS heterogeneity tests for the ADGC1 and ADGC2 subcohorts to
see if the might be reason to believe the MWAS results were likely to show variation
because of differences in the SNP association strengths across the cohorts. This
suggested that although there appears to be a slightl levels of inflation. Tables 4.4
and 4.5 provide a list of the most significant MWAS associated genes and gives the
SNP, the gene whose expression level is associated with that SNP, and the p-value
resulting from the MR tests for each of the two datasets (IGAP, ADGC). These tables
again suggest that outside the APOE gene and top associated SNVs on chromosome
19, i.e. PVRL2, Bin1, and CEACAM19, etc, little consistency exists between the MR
test results even though within some of the cohorts strong MR associations exist.
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Table 4.2: Top GWAS meta-analysis results derived from the metasoft program for
ADGC2.
4.5 Discussion
The complexities surrounding the pathobiology of AD make it difficult to iden-
tify genetically-mediated factors that might not only contribute to the disease, but
also act as potential targets for intervention and treatment. Although progress has
been made in characterizing aspects of the subclinical manifestations of AD using,
e.g., post-mortem brain samples and sophisticated neuroimaging techniques, these
studies often suffer from small sample sizes or a lack of integration with molecu-
lar phenotyping170. Obtaining molecular phenotypes associated with AD that could
reveal drug targets on large numbers of living humans is extremely difficult for prac-
tical and ethical reasons (e.g., brain biopsies are notoriously problematic and risky).
Therefore, practical alternatives are needed. GWAS initiatives have identified a few
genes that have acted as entry points into the pathobiology of AD, but have not
necessarily revealed many druggable factors171,172. As a result, we considered the use
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Table 4.3: Top GWAS meta-analysis results derived from the metasoft program for
IGAP.
Table 4.4: Top MWAS meta-analysis results derived from MRbase for ADGC.
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Table 4.5: Top MWAS meta-analysis results derived from MRbase for IGAP.
of emerging statistical analysis strategies rooted in MR tests and MWAS concepts,
in which GWAS data are repurposed to accommodate the imputation or assignment
of predicted molecular (or intermediate) phenotypes (IPs) to a cohort of individuals
based on their genetic profiles. These imputed or assigned molecular phenotypes can
then be tested for association with a trait. In this light, one can avoid costly and
problematic measurement of factors in less accessible tissues (like the brain) and still
obtain evidence implicating a molecular factor in the pathobiology of the disease (at
least if certain assumptions uphold).
We pursued an MWAS of AD that considered gene expression levels as candi-
date IPs. We leveraged available GWAS data on three very large cohorts. We used
the SNP-gene expression relationships in 44 tissues described in the GTEx database
as IPs in our MWAS as well as state-of-the-field MR test analytical methods to test
each SNP-gene expression pair’s relationship to AD. Unfortunately, we did not find
a great deal of consistency in the MWAS and individual MR test results across the
three cohorts, despite the fact we explicitly tested for heterogeneity in effect sizes and
found little evidence for heterogeneity. The exceptions involved the APOE gene, an
obvious factor in AD susceptibility, and a few other genes that exhibited marginally
significant associations in one or more of the cohorts, as noted in Table 4.5.
There are limitations to our study, however, despite the large sample sizes of
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the GWAS cohorts used and the state-of-the-field GTEx information and analytical
methods. For example, as noted, our ability to assess associations between predicted
gene expression and AD depends critically on how well we can predict gene expression
values from genetic variants through resources such as the GTEx database. This in
turn depends on the sample sizes in the GTEx database, the reliability of the gene
expression assays, and the how comprehensive the genotyping of the samples is. Many
research groups are seeking to improve and extend both databases like GTEx168 as
well as analytical methods for predicting gene expression values34, both of which
future work can take advantage of in studies of AD. In addition, the gene expression
data we used from GTEx was confined to 44 tissues whose relevance to AD may not be
the strongest. Despite this fact, we believe strategies such as MWAS and individual
MR tests have promise in elucidating both the pathobiology and drug targets complex
diseases like AD and could be pursued with other, perhaps more compelling, IPs, such
as protein levels, metabolite levels, lipid levels, or other factors once databases for
these factors are constructed in an analogous manner to GTEx.
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Chapter 5
Conclusions and Discussion
5.1 Summary
We have pursued a number of data analyses designed to identify and charac-
terize settings in which genetic effects on a human disease are context-dependent. We
focused on three broad settings. First, we considered issues surrounding the use of
DNA sequencing to facilitate clinical diagnoses and prognoses of patients infected with
MRSA. These issues considered how well sequencing could lead to appropriate diag-
noses as opposed to standard clinical culture-based systems. Secondly, we considered
how the reference genome choice impacts not only the identification of variants on
the MRSA genome, but also the association between genomic variation within strains
of MRSA. This was specifically for samples obtained from patients being treated in
a hospital for MRSA infection and patient outcomes. And lastly, we considered how
context-dependent variants associate with AD through tools which leverage Mende-
lain Randomization. We assessed these effects by testing whether or not a number
of variants associated with AD through intermediate phenotypes. In this particular
case we utilized particular gene expression levels to help identify groups of variants
associated with AD. We found evidence for context specificity in both settings. We
briefly summarize our findings for each of these activities below.
73
74
5.1.1 MRSA Whole Genome Sequencing vs. Standard Clini-
cal Identification Methods
We developed and implemented an end-to-end de novo assembly pipeline for
whole genome sequencing (WGS) and characterizing sequence variants for strains
of MRSA isolated from hospital patients. The purpose of this investigation was to
establish baseline accuracy for WGS based pathogen identification compared to gold-
standard clinical practices. In our pipeline, a successful identification was defined as
≥95% identity with an entry in the NCBI non-redundant bacterial sequence database
across≥25% of that species’ genome. Our study demonstrated that out of 350 samples
where WGS was implemented, roughly 10% (38 samples) showed discrepancies with
the standard clinical identification methods. Despite this discordance, WGS was able
to provide accurate and high resolution species identification with faster turnaround
times, increased cost effectiveness, and additionally was able identifying a number
a polymicrobial infections which would have been undetected through conventional
methods. Thus, DNA sequencing protocols have the potential to be more accurate in
MRSA pathogen identification than standard methodologies.
5.1.2 MRSA Reference Genome Implications for Investigating
Clinical Correlates
Genetic variation, i.e., the genetic background or mutational profile, of infec-
tious bacteria is understood to mechanistically decrease the efficacy of antimicrobial
treatments while increasing pathogenicity. Although many mutations exhibit a bi-
nary response in their ability to promote disease or virulence effects, heterogeneity in
the genetic background of infectious pathogens has been observed through numerous
whole genome sequencing investigations. This heterogeneity can exist with respect
to the either the presentation of clinical phenotypes stemming from host-pathogen
interactions or through differential outcomes for pathogenic virulence factors, where
a reference genome from a similar species of pathogen or comparator strain is utilized
for analytic purposes. Our investigation was designed to quantify the degree to which
the choice of a reference genome for identifying MRSA genetic variants impacts as-
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sessments of the correlations between in patient outcomes and MRSA genomic profile.
We found that choice of reference genome can significantly impact the correlation of
MRSA strains with clinical outcomes and antibiotic drug responses profiles. This
suggests that the context within which MRSA genomes are evaluated could impact
inferences about pathogen virulence.
5.1.3 Associating Alzheimer’s Disease Factors Through Inter-
mediate Phenotypes
The identification of genetic variants that influence susceptibility to AD is in-
tricate and complex for a number of reason as the previous section makes clear. Most
variants which associate with AD have weak to moderate effects, thus, this compli-
cates identifying disease contributing variants without large sample sizes. However,
through statistics its is possible to exploit biological links that exists between genetics
variants and AD, then the power to detect the effects of those variants, which may
increase power. We leveraged the use of mediator variables and a predicted interme-
diate phenotype, gene expression levels, to identify a relationship between AD and a
gene previously not thought to be associated with AD. We also found that there are
a group of potential genes that could impact AD using the same methodology and
further that some of these genes have a heterogeneous relationship with AD. Thus,
we were able to identify groups of variants whose association with AD can best be
brought to light by their impact on gene expression, this creating a context within
which their effects occur.
5.2 Limitations
Although we used what we feel are state-of-the-art genomic and clinical phe-
notype data sets, we recognize that inherent limitations exist that may impact both
the generalizability of the results of our analyses as well as direct interpretation of
our findings. We discuss some of the more salient limitations in isolation below.
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5.3 Small sample sizes
The sample sizes that we used for our studies were quite large relative to
other studies considered infectious disease and genetic association studies. However,
since the goal of our studies was to identify interactions and context-specific effects
of variants that might be subtle, even larger sample sizes would have been desirable.
5.3.1 Better and More Sophisticated Clinical Data and Out-
comes
For our MRSA studies exploring the clinical utility of genomic sequencing rel-
ative to the traditional culture-based pathogen identification methods, we would have
benefited from having more sophisticated outcome measures on a larger collection of
patients. For example, longitudinal data, host-specific factor characterization, med-
ication use, prior health issues, etc. information on the patients would have helped
put into our results into an even more compelling clinical context.
5.3.2 More reference genomes for MRSA project
Our analysis of the MRSA genomes and the choice of a reference genome
focused on the differences in interpretation when two different reference genomes are
used. Many other MRSA reference genomes have been discussed in the literature and
it would have been ideal had we been able to consider those genomes as well.
5.3.3 Additional ADGC Clinical Data to Refine AD Diagnosis
Our analysis of the ADGC data considered genotypes that were assigned or
imputed to individuals that did not have those genotypes. This imputation strategy
was pursued by the original ADGC investigative team. Unfortunately, the reliabil-
ity of the genotyping resulting from imputation strategies depends critically on the
imputation strategy itself. Although we have no reason to believe that our results
are not-trustworthy due to the imputation, it would have been better to use directly
genotyped variants rather than imputed variants in our analyses.
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5.3.4 Use of Quantitative Phenotypes for Association
We focused on AD diagnosis as our primary dependent variable, but we could
have benefited from an analysis of a subclinical phenotype, like cognitive decline or
cognitive score to reduce problems associated with criteria for AD diagnosis.
5.3.5 Greater Diversity of Individuals in our AD Study
Ironically, our studies of the context dependency of variants that influence
AD focused on individuals of largely European descent. It would have been ideal to
explore the effect of the variants on AD susceptibility in other genetic backgrounds.
This would allow us to test the hypothesis that greater context-dependency occurs,
whereby the variants in different ancestral populations modifies the influence of the
APOE4 allele on other variants.
5.3.6 GTEX Database Limitations
We used the GTEX database to build models relating genetic variants to gene
expression values. Although state-of-the-field, the GTEX database only contains
information on a few hundred individuals, which could compromise the power to
identify variant-gene expression associations. This could easily impact our ability to
relate predicted gene expression values to AD based on GTEX-derived models.
5.3.7 Prediction Modeling
As noted above, the assignment of predicted gene expression values to individ-
uals in the ADGC dataset depends critically on the reliability of the models relating
genetic variants to gene expression values. There are many ways to build such models.
A study comparing the different methods and how they might impact the results of
mediator analyses like ours would help put into context how sensitive our results are
to model choice.
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5.4 Future Directions
It is quite likely that as genomic and related technologies advance and become
more efficient, they will be used in a wide variety of settings in which context will
matter to an even greater degree. For example, we believe that at some point pathogen
sequencing will become routine in clinical settings. If this is will be the case, then
making sure the clinical impact of a particular pathogen is not in doubt will be crucial.
The reference-guided characterization of variants in pathogen genomes used to date
is complicated and potentially problematic, as our analyses suggest: if the mere
choice of a reference for variant identification and genome characterization can impact
interpretation, then the downstream clinical diagnostic and prognostic interpretation
of the pathogen is likely to be even more affected. Therefore, alternative strategies,
such as de novo assembly of pathogen genomes, are needed. In addition, greater
attention to host-related factors, such as a compromised immune system, co-infection,
or debilitating disease, will be necessary to understand the likely impact that an
infection may have on an individual’s health. These host-related factors can also
be characterized with genetic and related technologies. Thus, greater integration of
data sources will be required for the effective use of pathogen sequencing in clinical
practice.
In the context of the discovery of genetic factors that influence common chronic
conditions such as Alzheimer’s Disease (AD), not only will better strategies for identi-
fying variants that might be associated with AD be necessary, but also better charac-
terization of their likely functional impact will be necessary. The mere identification
of an associated variant - even in a context dependent manner - will not be as use-
ful as understanding the functional impact of the variant. Thus, more sophisticated
high-throughput functional assays, such as those leveraging emerging CRISPR-based
technologies173, will be essential for validating and putting into even more basic bio-
logical contexts the effects of genetic variants. Such studies can consider the influence
of genetic background by modifying the sequence of relevant constructs using cells or
organoids with different genetic backgrounds and then determining if the background
influenced the in vitro activity of the variant of interest. In addition, although we ex-
plored the use of gene expression levels as a ‘mediator’ between genetic factor effects
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and the clinical phenotype of AD, there are many other possibly mediators that could
have been used; for example, protein levels, metabolite levels, cognition scores, etc.
Future work will leverage information about these possible mediators to link genetic
variants to AD and other complex diseases using technology similar to what we used.
Ultimately, all of biology and life depends on the interplay of genetic, environmental
and stochastic factors. Believing that individual genetic factors will have robust and
completely reproducible effects within every genetic background and environment flies
in the face of this fact. Therefore, methodology that can accommodate and charac-
terize the context-specific effects of genetic factors is absolutely essential for moving
biology in a genomic era forward. When taken in this light, we hope that our work
will motivate future research.
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